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ABSTRACT 
 
 
THE PHARMACOLOGY OF AN AGONIST MEDICATION TO TREAT STIMULANT 
USE DISORDER 
 
Amy R. Johnson, Bachelor of Science 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of  
Doctor of Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2017 
 
Advisor: S. Stevens Negus, PhD Professor of Pharmacology and Toxicology 
 
Cocaine use disorder is a serious public health issue for which no approved 
pharmacotherapies exist. The development of a pharmacotherapy for cocaine use 
disorder is a priority for the National Institute on Drug Abuse. Amphetamine 
maintenance has been shown to be effective to reduce cocaine use in double-blind 
placebo controlled clinical trials, but has not been approved due to concerns over safety 
and abuse liability. Development of new pharmacotherapies is facilitated by preclinical 
testing for effectiveness and identification of new targets for medication development. 
The first part of this dissertation develops a novel non-human primate cocaine self-
administration choice procedure that is modeled after a human laboratory cocaine self-
administration choice procedure to improve translational research and facilitate 
medication development. The second part of this dissertation is devoted to examining 
the mechanisms of amphetamine maintenance-induced decreases in cocaine use. In 
the novel non-human primate choice procedure, monkeys chose between injections of 
  
 
cocaine or food pellets (0, 1, 3 or 10) in a 9-choice discrete trials procedure. The 
reinforcers were available on concurrent independent progressive-ratio schedules. 
Monkeys chose between cocaine and food in a dose- and magnitude-dependent 
manner. Maintenance on 7 days of lisdexamfetamine and amphetamine decreased 
cocaine choices without decreasing food responding, providing evidence that this model 
may be able to predict drugs that will have clinical efficacy to decrease cocaine use. 
The next set of experiments examined the effects of amphetamine maintenance on the 
abuse-related behavioral (intracranial self-stimulation, ICSS) and neurochemical 
[nucleus accumbens dopamine (DA) and serotonin (5-HT)] effects of cocaine, 
methylenedioxypyrovalerone, and methamphetamine in rats. Amphetamine 
maintenance produced sustained increases in ICSS baseline responding and nucleus 
accumbens DA levels without affecting 5-HT levels. Amphetamine maintenance also 
attenuated the behavioral and neurochemical abuse-related effects of cocaine but not 
those of methamphetamine, and with MDPV, amphetamine maintenance decreased the 
abuse-related neurochemical effect of MDPV, but not the abuse-related behavioral 
effect. This suggests that amphetamine would likely be most effective against cocaine, 
least effective against methamphetamine and between the two for MDPV. These data 
suggest targets that selectively release DA will be the most effective against cocaine 
use disorder.
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Chapter I 
Introduction 
 
Pharmacology of Monoamine Transporter Ligands 
Stimulants are a diverse class of drugs that typically increase locomotion, 
attention, wakefulness, heart rate, and blood pressure (Kirkpatrick et al, 2012; Rush et 
al, 2009). Most drugs in this class share a common mechanism of action; they interact 
with monoamine transporters to increase levels of the neurotransmitters dopamine 
(DA), serotonin (5-HT), and norepinephrine (NE). DA, 5-HT and NE are modulatory 
neurotransmitters with wide-reaching networks of neurons throughout the brain. The DA 
system includes 4 major pathways: the mesocortical (ventral tegmental area to the 
cortex), mesolimbic (ventral tegmental area to the nucleus accumbens), nigrostriatal 
(substantia nigra to the striatum), and the tuberoinfundibular (arcuate nucleus of the 
hypothalamus to the pituitary gland); these pathways regulate movement, executive 
function, learning, and addiction (Iversen and Iversen, 2007). Serotonergic pathways in 
the brain start in the raphe nuclei and project to almost all areas of the brain, including 
the cortex, hippocampus, amygdala, and ventral tegmental area (Beliveau et al, 2017; 
Charnay and Leger, 2010). This widespread network of neurons regulates appetite, 
feeding behavior, mood, and sleep (Jenkins et al, 2016; Yadav et al, 2009). There are 
several small nuclei containing cell bodies of noradrenergic neurons in the brain, and 
these nuclei send projections throughout the brain and spinal cord (Bruinstroop et al, 
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2013; Rinaman, 2011; Sara and Bouret, 2012). Norepinephrine is important in 
regulating attention, arousal, and memory (Berridge et al, 2013).  
These neurotransmitters are packaged into vesicles and released from neuron 
terminals in response to an action potential. Once the transmitters are released into the 
synapse, monoamine transporters are the primary mechanism for clearing monoamines 
from the extracellular space. Disrupting the function of the transporters greatly prolongs 
the amount of time the neurotransmitters spend in the synapse (Giros and Caron, 1993; 
Gowrishankar et al, 2014). The monoamine transporters consist of 12 membrane-
spanning domains and have phosphorylation sites on the c-terminus and n-terminus 
(both located on the intracellular side of the membrane) as well as glycosylation sites on 
extracellular loop 2 (McHugh and Buckley, 2015). These transporters use the 
electrochemical gradient maintained by the Na+/K+ pump to transfer a molecule of 
neurotransmitter along with 2 Na+ and 1 Cl- (for DA) or 1 Na+ and 1 Cl- (for NE and 5-
HT) from the extracellular space to the cytoplasm of the cell (Giros and Caron, 1993; 
Rudnick, 1977).   
Some stimulants bind to the transporter and prevent it from functioning properly, 
allowing the neurotransmitters to accumulate in the extracellular space and to continue 
to activate pre- and post-synaptic receptors. Evidence for this comes from synaptosome 
preparations where these drugs block uptake of radiolabeled ligands into the 
synaptosomes (Boja and Kuhar, 1989; Giros and Caron, 1993; Rothman et al, 2001) 
and from microdialysis studies showing increased extracellular DA and 5-HT after 
administration of cocaine (Andrews and Lucki, 2001). These drugs are referred to as 
uptake inhibitors; cocaine and methylenedioxypirovalerone (MDPV) are examples of 
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drugs that work in this way (Rothman et al, 2001; Schindler et al, 2016). Other drugs in 
this class act as substrates at the transporter and are shuttled into the cell through the 
transporter (Fleckenstein et al, 2007). These drugs then cause release of calcium from 
internal stores (Goodwin et al, 2009), bring depolarizing currents into the cell that may 
cause activation of voltage-gated calcium channels (Cameron et al, 2015), interact with 
vesicular monoamine transporter 2, collapse the pH gradient of the vesicles, and 
prevent loading of monoamines into the vesicles, causing the neurotransmitters to 
accumulate in the cytoplasm of the cell (Fleckenstein et al, 2007). This results in efflux 
of the neurotransmitter into the synaptic space through the transporter (Kahlig et al, 
2005). Drugs that work in this way are called releasers; amphetamine and 
methamphetamine fall into this category of stimulants.  
Stimulants also vary in their selectivity at the DA, 5-HT, and NE transporters 
(DAT, SERT, NET, respectively). Some drugs are relatively nonselective and will 
interact with all 3 transporters at relatively equal doses; cocaine and 
metheylenedioxymethamphetamine are examples of relatively nonselective drugs 
(Rothman et al, 2001).  Others may have a preference for one or two transporters, such 
as MDPV (which is a highly selective DAT and NET inhibitor) and amphetamine (which 
is a selective substrate at DAT and NET > SERT) (Rothman et al, 2001; Schindler et al, 
2016). Still other drugs can have mixed action between different transporters.  For 
example, N-ethyl 4-methylamphetamine is an uptake inhibitor at DAT, but a releaser at 
NET and SERT (Solis et al, 2017).   
 The abuse liability of monoamine uptake inhibitors and releasers has been 
studied extensively and has been found to be correlated with the selectivity of the 
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compound for DAT versus SERT. One of the first experiments to observe this effect 
studied a series of cocaine analogs with different DAT versus SERT selectivity in drug 
self-administration under a progressive-ratio schedule of reinforcement in rats (Roberts 
et al, 1999). The rats were trained to self-administer cocaine under the progressive-ratio 
schedule, and then the novel compounds were substituted for the cocaine. Compounds 
selective for SERT did not support break points different from saline substitution, but 
drugs selective for DAT supported break points similar to or greater than cocaine. 
Another series of experiments examined the effects of amphetamine analogs with 
similar potencies at DAT but with varying potencies at SERT in drug self-administration 
under fixed-ratio and progressive-ratio schedules of reinforcement in non-human 
primates (Wee et al, 2005). In this study, all compounds were self-administered, but the 
drug that was the most selective at SERT was self-administered at lower rates than the 
other compounds and supported lower break points than the other more DAT-selective 
compounds. A later study found that another more SERT-selective amphetamine 
analog increased both DA and 5-HT in rats and did not function as a reinforcer in drug 
self-administration under a fixed-ratio schedule of reinforcement in non-human primates 
(Rothman and Baumann, 2006). Similarly, in 2 intracranial self-stimulation studies, 
compounds that were more potent at DAT than SERT produced greater abuse-related 
effects than compounds that were more potent at SERT rather than DAT (Bauer et al, 
2013; Suyama et al, 2016).  
Stimulants like cocaine (relatively equal potency to increase DA and 5-HT; 
Rothman et al, 2001), methamphetamine (~40 times more potent to increase DA than 5-
HT; Rothman et al, 2001), and MDPV (at least 100 times more potent to increase DA 
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versus 5-HT; Baumann et al, 2013) have been shown to have abuse liability in the 
human population. According to the National Survey on Drug Use and Health, in the 
United States in 2016, approximately 1.9 million people were current users of cocaine 
(had used in the past month), and 889,000 reported a cocaine use disorder within the 
past year (SAMSHA, 2017). In the same survey, methamphetamine current use was 
somewhat lower than cocaine at 664,000 past-month users, but past-year 
methamphetamine use disorders came in at 684,000 people, providing evidence that 
methamphetamine use is also problematic (SAMSHA, 2017). MDPV is a synthetic 
cathinone known as a “bath salt”; the number of MDPV users is not well-established 
(SAMSHA does not ask specifically about MDPV or other bath salts), but there is 
evidence from emergency department visits, deaths, and online sites where users 
record their experiences that MDPV is used and abused by humans (Center for Disease 
Control, 2011; Karila et al, 2017; Wright et al, 2013). 
 
Overview of Treatments for Stimulant Use Disorders 
Currently, there is demand for a treatment for abuse of and addiction to stimulant 
drugs. A Cochrane review found cognitive behavioral therapy and contingency 
management to be better than no treatment on some end points such as treatment 
retention and continuous abstinence, but only contingency management was able to 
retain the abstinence effect at follow up (Minozzi et al, 2016). Another intervention 
strategy that has been tried is physical exercise. Studies have seen reduced cocaine 
use, reduced methamphetamine use, and changes in DA-receptor availability in 
methamphetamine users after exercise. However, one recently completed study found 
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no difference in percent of days abstinent from stimulants between an exercise and a 
control group, even though both groups achieved high abstinence rates (Trivedi et al, 
2017). Despite the clinical efficacy of these treatment methods, relapse rates are still 
high, and there is need for better treatments or pharmacotherapies that can be used in 
conjunction with psychotherapy or other interventions to increase treatment success 
and decrease relapse.  
The National Institute on Drug Abuse has made finding a pharmacotherapy for 
cocaine abuse a priority for over 25 years. Hundreds of clinical trials have been funded 
to investigate pharmacotherapies for cocaine or methamphetamine use disorder. 
However, there is not currently a pharmacotherapy approved for cocaine or 
methamphetamine use disorder by the Food and Drug Administration.  
Pharmacotherapies can be sorted into 2 general categories: antagonist- or 
agonist-based. Antagonist pharmacotherapies oppose the effects of the drug of abuse 
or prevent the drug from reaching its target. For stimulants, the antagonist therapies 
would include DA receptor antagonists, drugs that decrease levels of DA, drugs that 
increase the metabolism of DA, or vaccines that prevent the abused stimulants from 
crossing the blood-brain barrier. The direct DA-receptor antagonists (e.g. haloperidol, 
chlorpromazine) have been tried and have failed in clinical trials for cocaine use 
disorder; compliance and dropout rate are often major issues with these drugs because 
of the undesirable side effects that they cause (Grabowski et al, 2000; Kishi et al, 2013). 
This type of therapy has received new life with the current interest in studying 5-HT2c 
receptor agonists and 5-HT2A receptor antagonists with the goal of reducing DA neuron 
firing and thereby decreasing DA release in the nucleus accumbens (NAc) (Howell and 
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Cunningham, 2015). To date, these therapies have shown promise in some pre-clinical 
models of drug addiction (Gerak et al, 2016; Harvey-lewis et al, 2016), and are currently 
in clinical trials for cocaine and methamphetamine use disorders. However, they did not 
reduce cocaine or methamphetamine choice in non-human primates (Banks, 2016; 
Banks and Negus, 2016).  
Agonist pharmacotherapies are drugs that produce pharmacodynamic effects 
similar to those of the drug of abuse and that may substitute for or prevent withdrawal 
from the abused drug. One drawback to agonist therapies is they often have abuse 
potential because they mimic the effects of the drug of abuse. To combat these effects, 
an ideal agonist pharmacotherapy would have a slow onset of effects and long duration 
of action, two pharmacokinetic factors that will decrease abuse liability of the 
pharmacotherapy (Negus and Henningfield, 2015; Rush and Stoops, 2012). For abused 
stimulants, agonist pharmacotherapies have focused on DA, 5-HT, and to some extent 
NE. In general, this type of therapy has been largely ineffective in clinical trials, with only 
amphetamine and bupropion being identified as drugs that have potential to decrease 
cocaine-taking by a Cochrane review (Castelles et al, 2016). Other potential agonist 
pharmacotherapies, such as methylphenidate (DA and NE), fluoxetine (and other 
selective serotonin reuptake inhibitors), and tricyclic antidepressants (which increase 5-
HT and NE) have not yielded consistent results in clinical trials. Amphetamine 
maintenance has been tested against cocaine use disorder in double-blind placebo 
controlled clinical trials and has consistently performed better than placebo.  
 
Amphetamine Maintenance for Cocaine Use Disorder  
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Clinical Trials. Amphetamine was first tested against cocaine use disorder in a 
double-blind placebo-controlled clinical trial (Grabowski et al, 2001). In this study, 
subjects meeting the DSMIV criteria for cocaine dependence were administered oral d-
amphetamine over a 3-month period. There were 3 groups of subjects in this study: a 
placebo group, a low-dose d-amphetamine group who received 15 mg/day for the first 
month and then 30 mg/day for the final 2 months, and a high-dose d-amphetamine 
group who received 30 mg/day in the first month and 60 mg/day in the final 2 months. 
The main measure of efficacy in this study was the proportion of urine samples positive 
for benzoylecgnine (BE, a cocaine metabolite). In month 3, significant differences were 
noted between the placebo and high-dose groups, with the high-dose group providing 
lower proportion of BE-positive urines. However, these findings must be interpreted with 
caution, however, as individuals in the high dose-group succumbed to high rates of 
attrition during the study.  
After the initial clinical trial that suggested d-amphetamine maintenance may 
have some clinical utility in treating cocaine use disorder, several additional trials have 
been conducted to evaluate the effects of amphetamine in combination with other 
drugs. d-Amphetamine was again studied in combination with methadone in a group of 
dual cocaine and heroin users (Grabowski et al, 2004a). d-Amphetamine doses were 
the same as in the previous study (placebo, low dose 15-30mg/day, and high dose 30-
60mg/day); however, all groups received the same dose of methadone treatment in 
addition to the d-amphetamine or placebo treatments. Similar to the previous study, the 
high-dose d-amphetamine group had a decreased proportion of BE-positive urine 
samples as compared to placebo in months 2 – 4 of the study. Another combination that 
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was tried was d-amphetamine with the low-potency DA uptake inhibitor modafinil 
(Schmitz et al, 2012). Neither modafinil alone (400 mg) nor the combination of d-
amphetamine (30 mg) plus modafinil (200 mg) was effective at reducing cocaine use, 
but the amphetamine-alone (60 mg) and placebo groups saw small reductions in the 
proportion of BE-positive urines. In line with the previous studies, the amphetamine-
alone group had a lower proportion of BE-positive urines as compared to the placebo 
group for the first few months, however, by the end of the trial period these differences 
were no longer present. Another combination study was done with extended-release 
mixed amphetamine salts and the anticonvulsant topiramate compared to placebo, but 
the drugs were not tested separately (Mariani et al, 2012). The combination doses of 
amphetamine and topiramate were determined individually for each subject by gradually 
increasing the dose up to a daily maximum of 60 mg amphetamine and 300 mg 
topiramate. Reductions in dose were made for any intolerable adverse side effects. The 
group getting amphetamine and topiramate was more likely to achieve 3 consecutive 
weeks of abstinence, defined as BE-negative urine for 3 weeks in addition to self-
reports of no cocaine use during that 3 week period, as compared to the group getting 
placebo.  
Two other recent clinical trials have examined the effects of amphetamine alone 
as a treatment for cocaine use disorder. One used a sub-population of cocaine users 
with attention-deficit/hyperactivity disorder (ADHD). As several effective ADHD 
medications are indirect DA agonists like cocaine, it is conceivable that cocaine users 
who have ADHD are using cocaine to self-medicate. If this is true, administration of an 
FDA-approved ADHD medication should decrease ADHD symptoms and decrease 
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cocaine use in this population. Consistent with that hypothesis, there was improvement 
in ADHD symptoms as well as reductions in cocaine use (assessed by urine BE levels 
and self-report) in the groups treated with extended-release mixed amphetamine salts 
(60 or 80 mg) as compared to groups getting placebo treatment (Levin et al, 2015). The 
other clinical trial was conducted as a multi-site trial in the Netherlands in a heroin-
dependent population who also met criteria for cocaine dependence and had made at 
least two attempts to quit cocaine use previously (Nuijten et al, 2016). The participants 
were maintained on oral methadone (up to 150 mg) and allowed supervised use of 
pharmaceutical-grade diacetylmorphine (up to 1000 mg). Extended release d-
amphetamine (60 mg) was superior to placebo in decreasing number of days of cocaine 
use, increasing average number of consecutive abstinence days (both assessed by 
self-report), and decreasing proportion of BE-positive urines in the final 4 weeks of the 
study.  
Meta-analyses of clinical trials have also concluded that amphetamine treatment 
may have some utility for treatment of cocaine dependence (Castelles et al, 2016). 
Even though treatment effects are generally small, about 30% of amphetamine-treated 
participants are able to achieve 3 weeks continuous abstinence from cocaine as 
compared to 6%-13% of patients getting placebo (Mariani et al, 2012; Nuijten et al, 
2016). This treatment effect is comparable to that of the most effective 
pharmacotherapies approved to treat abuse of substances in other drug classes. For 
example, in one clinical trial of treatments for opioid addiction, about 30% of patients 
treated with a high dose of methadone were able to achieve 4 weeks of continuous 
abstinence as compared to 8% of patients who got a low dose of methadone (Johnson 
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et al, 2000). Similarly, in a clinical trial for nicotine dependence, 26-38% of patients 
achieved 12 weeks continuous abstinence when treated with nicotine patches or 
varenicline as compared to 13% of patients who received placebo (Anthenelli et al, 
2016). Taken together, these data suggest that, as measured by abstinence from the 
drug of abuse, amphetamine maintenance appears to be as effective to treat cocaine 
use disorder as other approved pharmacotherapies are to treat other substance use 
disorders. This is in contrast to other potential pharmacotherapies for cocaine abuse 
including antidepressants, anticonvulsants, and antipsychotics, which have not 
demonstrated efficacy to reduce cocaine use in double-blind placebo-controlled clinical 
trials (for reviews see: Indave et al, 2016; Minozzi et al, 2011; Pani et al, 2011).  
Human Laboratory Studies. The effect of amphetamine maintenance on 
cocaine-taking behavior in human laboratory experiments has been examined a few 
times. In one study, subjects were maintained on placebo and 40 mg/day d-
amphetamine (treatment condition order was counterbalanced across subjects) for 7 
days and given a choice between 4 mg cocaine (placebo) and 4, 10, 20, or 30 mg 
intranasal cocaine (Rush et al, 2010). All drugs were administered under double-blind 
conditions. Amphetamine maintenance attenuated choice of the 20 mg dose of cocaine 
as compared to the choice under placebo treatment. Amphetamine maintenance has 
also been studied on the effects of cocaine + hydromorphone (speedball) administration 
in the human laboratory (Greenwald et al, 2010). Subjects were maintained on 8 
mg/day buprenorphine as well as 0, 30, and 60 mg/day sustained release d-
amphetamine presented in ascending dose order under double-blind conditions. 
Amphetamine maintenance was found to decrease break points for cocaine (8 mg 
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intranasal) but not for hydromorphone (2 mg intramuscular) alone or cocaine + 
hydromorphone (speedball).  
The results from these human laboratory experiments are consistent with the 
outcomes of clinical trials. In both types of experiments, amphetamine maintenance 
decreased cocaine self-administration. This adds to the data collected from clinical trials 
in which researchers are collecting data on measures related to cocaine self-
administration (e.g. urine BE levels), but are not measuring the cocaine-taking behavior 
directly.  
Preclinical. The preclinical work on the effect of amphetamine maintenance on 
the effects of cocaine-taking behavior started with a cross-tolerance experiment in 
which the researchers gave twice daily injections of amphetamine and looked at effects 
on cocaine discrimination as well as self-administration (Peltier et al, 1996). The highest 
dose of amphetamine maintenance (3.2 mg/kg/injection) produced cross-tolerance to 
the discriminative stimulus properties of cocaine, decreased cocaine break points, and 
produced an approximately 3-fold rightward shift in the FR-based cocaine self-
administration dose-effect curve. The next preclinical study did not occur until after the 
2001 clinical trial showing some potential clinical utility for amphetamine. A series of 
studies showed that amphetamine maintenance decreased response rates, injections, 
and breakpoints for cocaine self-administration in nonhuman primates (Negus and 
Mello, 2003a, 2003b). They also showed that this effect was relatively selective for 
cocaine- versus food-maintained responding and that amphetamine effects on food-
maintained behavior were less consistent and smaller in magnitude than the effects of 
amphetamine on cocaine-maintained behavior. In a parallel study, a choice procedure 
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was used to determine the effects of amphetamine maintenance on cocaine preference 
versus an alternative food reinforcer in non-human primates (Negus, 2003). 
Amphetamine maintenance decreased cocaine preference as compared to food in this 
choice procedure. This study showed that amphetamine maintenance was able to 
decrease responding for cocaine and at the same time reallocate behavior toward an 
alternative food reinforcer, further suggesting that the rate-decreasing effects of 
amphetamine maintenance are selective for cocaine and not due to non-selective 
amphetamine effects on motor behavior. 
A rodent cocaine self-administration experiment provided additional information 
about the effects of amphetamine on cocaine-taking behavior. This study replicated the 
previous findings that amphetamine maintenance decreases cocaine-taking behavior; 
however, the effect was dependent on cocaine dose (Chiodo et al, 2008). Self-
administration of low doses of cocaine was attenuated by amphetamine maintenance, 
but self-administration of high cocaine doses (0.75 and 1.5 mg/kg/inj) were unaffected. 
Additionally, cocaine had to be actively self-administered during amphetamine 
maintenance in order for the cocaine-decreasing effect to be expressed. Follow up 
studies in nonhuman primates (Czoty et al, 2010) and in rodents (Zimmer et al, 2014) 
underscored the importance of active cocaine self-administration while amphetamine is 
in the system to be able to detect the effect of amphetamine maintenance on cocaine-
taking behavior.    
Other studies in nonhuman primates and in rodents have also identified cocaine 
dose as a variable that is important in determining the effects of amphetamine on 
cocaine-taking behavior. Larger doses of cocaine are resistant to reductions in choice 
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and rate of responding by amphetamine maintenance. This effect may be somewhat 
species-dependent, as rodents saw no benefit from increased length of amphetamine 
exposure or of a higher amphetamine dose in decreasing high-dose cocaine self-
administration (Chiodo and Roberts, 2009). Consistent with those findings, a rodent 
choice procedure showed that neither 0.1 nor 0.32 mg/kg/hr amphetamine showed the 
ability to decrease the preference for the highest cocaine dose, even though preference 
for lower cocaine doses was decreased (Thomsen et al, 2013). On the other hand, non-
human primates showed decreased cocaine preference at the high cocaine dose after 
14, but not 7, days of 0.1 mg/kg/hr amphetamine maintenance (Banks et al, 2013). 
Additionally, a study showed that cocaine-taking behavior could be decreased in all 
monkeys in the experiment, although a higher cocaine self-administration dose (0.1 vs. 
0.03 mg/kg/inj) in one monkey took a higher amphetamine dose (0.056 vs. 0.01 – 0.03 
mg/kg/inj) to decrease the cocaine-taking behavior(Czoty et al, 2011).  
 
Amphetamine Maintenance for Methamphetamine Use Disorder 
Amphetamine maintenance has been less successful to treat methamphetamine 
use disorder than cocaine use disorder. Early retrospective studies examined the 
effects of oral dexamphetamine for amphetamine (including methamphetamine) use 
and saw up to 70% of users were able to stop taking street drugs (Charnaud and 
Griffiths, 1998; White, 2000). However, those studies were not placebo-controlled, and 
a later open-label placebo-controlled study found that both placebo and amphetamine 
groups decreased amphetamine use with no between-group differences in retention or 
amphetamine use (Shearer et al, 2001). A double-blind placebo-controlled clinical trial 
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found greater retention in the amphetamine group, and both groups decreased 
methamphetamine use over the course of the trial; however, there were no between-
group differences in methamphetamine use by self-report or by hair-sample analysis 
(Longo et al, 2010). Another double-blind placebo controlled clinical trial found no 
difference in methamphetamine-positive urines between the placebo group and the 
amphetamine group (Galloway et al, 2011); however, user-rated withdrawal severity 
and methamphetamine cravings were lower in the amphetamine group.  
Amphetamine maintenance did not decrease methamphetamine self-
administration in a human laboratory self-administration experiment, but did decrease 
cardiovascular effects of methamphetamine as well as subject-rated subjective effects 
of methamphetamine (Pike et al, 2014). In a non-human primate methamphetamine-
versus-food choice procedure, 7 days of amphetamine maintenance was not effective to 
decrease methamphetamine choice in group data; however, in 2 of the 4 monkeys 
methamphetamine choice was completely eliminated while methamphetamine choice 
was increased in the other 2 monkeys (Schwienteck and Banks, 2015). This 
demonstrates the individual variability of amphetamine effects on methamphetamine-
taking behavior and matches the effects seen in the clinical trials and self-administration 
studies. 
 
Limitations to Amphetamine Maintenance for Stimulant Use Disorders 
Taken together, the body of literature suggests clinical utility for amphetamine 
maintenance in treating cocaine use disorder, but not methamphetamine use disorder. 
Most clinical trials show a benefit of amphetamine maintenance over placebo on 
 16 
 
measures such as abstinence from cocaine and proportion of cocaine-positive urines. 
Preclinical and human laboratory data support these findings and show that 
amphetamine maintenance decreases rates of cocaine self-administration, break points 
in progressive ratio procedures, and cocaine preference in choice procedures.  
However, there are limitations to the efficacy of amphetamine. Clinical trials show 
a greater decrease in cocaine use in amphetamine-maintained patients as compared to 
placebo, but only approximately 30% of amphetamine-maintained subjects remain 
abstinent from cocaine for 3 continuous weeks (Mariani et al, 2012). The clinical and 
pre-clinical data reviewed above suggest that amphetamine dose, active cocaine self-
administration while amphetamine is on board, length of treatment, and cocaine dose 
are relevant factors in how amphetamine will work against cocaine use disorder.  
In addition to its limited effectiveness for treatment of cocaine use disorder, 
amphetamine maintenance has not demonstrated success in decreasing 
methamphetamine use. This limitation shows that the therapeutic effects of 
amphetamine maintenance in cocaine use disorder do not generalize to all other 
stimulants. With the relatively recent emergence of new abused stimulants such as 
synthetic cathinones (De Felice et al, 2014; Karila et al, 2017; Schindler et al, 2016), it is 
important to know whether amphetamine maintenance may be successful against use 
disorders involving stimulants other than cocaine and what factors may predict whether 
amphetamine maintenance will be effective against a substance use disorder. 
Understanding the mechanisms responsible for reductions in cocaine use associated 
with amphetamine maintenance may also lead to development of new therapeutic 
targets for potential pharmacotherapies.  
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Dissertation Goals 
In view of the promising but limited effectiveness of amphetamine maintenance 
to treat cocaine use disorder, the present dissertation project had two goals.  First, the 
discovery of improved pharmacotherapies will rely in part on preclinical-to-clinical 
translational studies of treatment effectiveness in assays of abuse-related cocaine 
effects.  A working hypothesis by our research group has been that this translational 
research effort would benefit from development of drug self-administration models that 
are highly homologous in animal and human subjects and thereby minimize the 
potential for procedural variables to confound preclinical-to-clinical translation of results.  
Funding was acquired under an R01 grant to test this hypothesis, and my role was to 
develop a drug self-administration procedure in rhesus monkeys homologous to a 
similar procedure being developed by colleagues at the University of Kentucky for use 
in humans. The development of this procedure and evaluation of its sensitivity to 
maintenance on amphetamine and the amphetamine prodrug lisdexamfetamine are 
described in Chapters 2 and 3.  A second goal of this dissertation was to examine 
potential mechanisms of selective amphetamine effectiveness as a maintenance 
medication for treatment of addiction to cocaine but not methamphetamine.  These 
studies were conducted using parallel behavioral and neurochemical procedures in rats, 
and results and implications of these studies are described in Chapter IV of the 
dissertation.  The dissertation concludes with a discussion of overall implications and 
potential future directions.  
Translational Methods Development. Mechanistic studies are often performed 
using pre-clinical research with the ultimate goal of finding a new target for future 
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development of candidate pharmacotherapies. Clinical trials are expensive, and the 
medications tested must be approved for human use or be extensively evaluated 
preclinically to determine safe doses for testing in humans. Subsequently, pre-clinical 
models are practical alternatives for use in testing mechanisms of amphetamine 
maintenance-induced decreases in drug-taking behavior.  
However, the pre-clinical model needs to be predictive of clinical efficacy of the 
potential pharmacotherapy. This presents a challenge for stimulants because there are 
no approved pharmacotherapies that can be used to validate pre-clinical models. 
Nonetheless, the efficacy of amphetamine maintenance to decrease cocaine use in 
double-blind placebo-controlled clinical trials suggests that amphetamine maintenance 
can be used as a positive control in preclinical studies, whereas treatments that have 
failed in the clinic can be used as negative controls. One pre-clinical model that has 
consistently displayed sensitivity to amphetamine maintenance effects on cocaine use 
has been self-administration using choice procedures. In choice procedures, subjects 
have simultaneous access to both a drug of interest (e.g. cocaine) and a non-drug 
alternative reinforcer (e.g. food), and data are collected both on the allocation of 
behavior between the drug and non-drug reinforcers and on the overall rate of behavior 
emitted for both reinforcers (Banks et al, 2015b; Banks and Negus, 2012). In these 
procedures, the optimal outcome of a candidate pharmacotherapy is a reallocation of 
behavior away from drug choice and toward choice of the alternative without a change 
in the overall rates of behavior. Conversely, poor outcomes in choice procedures 
include increases in cocaine choice or no change in cocaine choice up to doses that 
produce decreases in overall rates of responding. This effectiveness of choice in 
 19 
 
identifying potentially efficacious pharmacotherapies carries over to the human 
laboratory, where choice studies (usually drug versus money) have been implemented 
to study the effects of potential pharmacotherapies. Drugs that have been effective to 
decrease preference of the drug versus the alternative reinforcer in the lab are also 
typically effective at reducing drug use in the clinic (Czoty et al, 2016).  
In the pharmacotherapy development process, if a drug has shown effectiveness 
in the pre-clinical choice model, it would then be warranted to test the drug in a human 
laboratory choice setting to learn more about its effectiveness in people and its potential 
side effects before proceeding to a clinical trial. Chapter II & III of this dissertation will 
deal with development of a novel cocaine-versus-food choice procedure in non-human 
primates based on a choice procedure from the human laboratory. This procedure has 
the advantage of being modeled after the human laboratory choice studies and so may 
minimize any impact of differences in procedural variables in predicting what will work in 
the human laboratory. This procedure was validated with amphetamine maintenance 
and tested with lisdexamfetamine, a clinically available amphetamine prodrug that is 
also under consideration as an agonist pharmacotherapy for cocaine use disorder. At 
the same time, a collaborator developed the homologous choice procedure in human 
subjects and conducted parallel studies with amphetamine maintenance.  
Mechanisms of Amphetamine Maintenance Effects. Amphetamine is often 
thought of as an agonist-type medication for stimulant use based on its neurochemical, 
behavioral, and discriminative stimulus effects (Herin et al, 2010; Negus and 
Henningfield, 2015; Rush and Stoops, 2012). However, cocaine interacts with the 
monoamine transporters differently than amphetamine and methamphetamine. The end 
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result of all three drugs is accumulation of extracellular DA, NE, and 5-HT, but there are 
other end points on which these drugs can oppose each other. Cocaine can block 
effects of amphetamine in vitro (presumably blocking access to the transporter binding 
site for amphetamine (Kahlig et al, 2005); amphetamine brings a depolarizing current 
through the transporter in oocyte preparations, conversely, cocaine causes a 
hyperpolarizing current (Cameron et al, 2015). Uptake inhibitors and releasers also tend 
to have opposite effects on monoamine transporter expression, with uptake inhibitors 
increasing expression of the transporters and releasers decreasing expression of the 
transporters (Kahlig and Galli, 2003; Kittler et al, 2010). This evidence suggests that the 
difference in the interaction at the transporter between cocaine and methamphetamine 
may be a potential factor in whether amphetamine maintenance will be effective in 
reducing a drug’s abuse liability.  
Another factor that may play a role in the differential effect of amphetamine 
maintenance on use of cocaine versus methamphetamine is the DAT versus SERT 
selectivity profile of the two drugs. Cocaine is relatively non-selective between DAT and 
SERT, whereas methamphetamine is more DAT-selective. As much evidence has 
supported the selectivity of compounds for DAT versus 5-HT as a key factor in abuse 
liability, it could be that the DA-selective profile of methamphetamine is harder to treat. 
The DAT-selective uptake inhibitor, MDPV, provides a way to test between these two 
possibilities. If amphetamine maintenance decreases abuse-related effects of MDPV, it 
is more likely that amphetamine maintenance will work against abuse of other 
monoamine uptake inhibitors. If amphetamine maintenance does not decrease the 
abuse-related effects of MDPV, the selectivity profile is potentially an explanation. There 
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is no clinical or pre-clinical data on the effect of amphetamine maintenance on MDPV, 
so these effects remain to be seen.  
Intracranial self-stimulation (ICSS) is a pre-clinical procedure that can be used to 
evaluate the abuse-related effects of drugs in rats (Negus and Miller, 2014). An 
electrode is implanted into the medial forebrain bundle, and the rats are allowed to 
press a lever to receive electrical stimulation of that brain area. The frequency of the 
electrical brain stimulation can be manipulated through the behavioral session to 
provide a dynamic range of low- to high-rate behavior to study. When drugs of abuse 
such as cocaine, methamphetamine, or MDPV are given prior to an ICSS session, a 
leftward shift of the frequency-rate curve is produced, and this is indicative of an abuse-
related effect. One previous study has found that implanting rats with osmotic 
minipumps filled with either 0.32 mg/kg/hr amphetamine shifted the ICSS frequency-rate 
curve to the left for the duration of the treatment and attenuated the abuse-related 
effects of a high cocaine dose (10 mg/kg) on ICSS (Bauer et al, 2013), which aligns with 
the other clinical and pre-clinical data on amphetamine maintenance for cocaine. 
Chapter IV of this dissertation will expand upon those data in several ways. First, a 
wider range of cocaine doses was tested during maintenance on a range of 
amphetamine doses. Second, the abuse-related effects of a range of methamphetamine 
and MDPV doses were also tested during amphetamine maintenance. Effects of 
methamphetamine and MDPV have not been tested previously during amphetamine 
maintenance in this procedure, and testing these drugs will give valuable information on 
the validity of ICSS as a model for pharmacotherapy development. If amphetamine 
attenuates the abuse-related effect of methamphetamine, this may not be a good 
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predictive model of clinical effects. Alternatively, if amphetamine fails to attenuate the 
abuse-related effects of methamphetamine ICSS may be a good predictive model, and 
the results from MDPV tests will provide some answers about the mechanism of 
amphetamine effects. If the amphetamine effect on the abuse-related effects of MDPV 
looks more like the effect on cocaine, the interaction at the transporter is likely a key 
factor in determining amphetamine effects on these drugs. On the other hand, if the 
amphetamine effect on the abuse-related effects of MDPV looks more like the effect on 
methamphetamine, the DAT versus SERT selectivity is probably an important factor in 
amphetamine effects on stimulants.  
An increase in NAc DA levels is a neurochemical abuse-related effect of drugs 
that can be measured using rats. Cocaine, methamphetamine and MDPV all increase 
NAc DA levels (Andrews and Lucki, 2001; Baumann et al, 2012; Schindler et al, 2016) 
Since the selectivity ratio of a drug to interact with DAT versus SERT is important in 
modulating the abuse-related effect (Bauer et al, 2013; Bonano et al, 2014), a 2nd 
experiment in Chapter IV presents the effects of amphetamine maintenance on 
modulation of DA and 5-HT levels by cocaine, methamphetamine, and MDPV. These 
experiments continue to probe the mechanism of amphetamine effects on cocaine and 
other stimulants, with the hypothesis that amphetamine maintenance would attenuate 
the cocaine- and MDPV-mediated DA increases, but will not affect the 
methamphetamine increases.  Additionally, because amphetamine itself is relatively 
selective as a substrate at DAT vs. SERT, we also hypothesized that amphetamine 
maintenance would not alter 5HT increases produced by cocaine or methamphetamine.  
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Lastly, the effects of amphetamine maintenance on striatal dopamine transporter 
(DAT) binding were assessed. There is evidence that large doses of releasers or 
chronic treatment with releasers may decrease DAT binding (Fleckenstein et al, 2007). 
This may be indicative of a neurotoxic effect, so it is important to know whether 
regimens of amphetamine maintenance that decrease cocaine choice and attenuate 
abuse-related effects of cocaine will cause a decrease in DAT binding.  
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Chapter II 
Development of a Translational Model to Screen Medications for Cocaine Use 
Disorder: Choice Between Cocaine and Food in Rhesus Monkeys  
(Drug Alcohol Depend 165:103-110, 2016) 
 
Introduction 
Cocaine use disorder remains a significant clinical challenge for which there are 
no medications currently approved by the Food and Drug Administration.  Research to 
evaluate the efficacy and safety of new medications for drug abuse or other disorders 
benefits from a translational path from preclinical to clinical studies, and a key step 
along this path occurs at the transition from research in animals to human subjects 
(Comer et al, 2008; Haney and Spealman, 2008a; Mello and Negus, 1996; Rush and 
Stoops, 2012).  A change in species is unavoidable at this transition; however, the 
fidelity of translation may benefit from both (1) use of nonhuman primates as animal 
subjects due to their high degree of homology with humans, and (2) use of analogous 
experimental procedures that minimize discrepancies in variables other than species 
(Czoty et al, 2016; Foltin et al, 2015; Weerts et al, 2007; Yu, 2011). 
In view of these considerations, the goal of this project and the companion study 
conducted in humans (Lile et al, 2016) was to develop homologous drug self-
administration procedures in nonhuman primates and humans as a platform for more 
efficient and reliable translational research on candidate medications to treat drug 
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abuse.  In particular, these studies sought to harmonize three sets of procedural 
variables: (1) the route and doses of self-administered cocaine, (2) the schedule of 
reinforcement that governed availability of cocaine and an alternative non-drug 
reinforcer, and (3) the treatment regimen for delivery of a candidate medication.  With 
regard to the schedule of self-administration, previous human-laboratory studies have 
identified concurrent independent progressive-ratio schedules of choice between drug 
and money as a sensitive tool for medication evaluation (Jones and Comer, 2013; 
Moeller and Stoops, 2015; Stoops et al, 2012; Sullivan et al, 2006).  Accordingly, 
cocaine self-administration was established in rhesus monkeys and human subjects 
under nearly identical concurrent independent progressive-ratio schedules of choice 
between cocaine and a species-specific non-drug alternative reinforcer (food in 
monkeys; money in humans).  The cocaine dose and magnitude of the non-drug 
alternative were then systematically manipulated in each species, with the same unit 
doses of cocaine being used in both species.  Results are reported here for the study in 
nonhuman primates and in a companion paper for the study in human subjects (Lile et 
al., 2016; see companion paper in this issue).  We hypothesized that comparable 
patterns of cocaine choice could be demonstrated in rhesus monkeys and humans, and 
that specific parameters of cocaine dose and alternative reinforcer magnitude could be 
identified for subsequent evaluation of candidate medications in both species.   
The present study also evaluated effects of lisdexamfetamine as a representative 
candidate medication.  Lisdexamfetamine is an amphetamine prodrug approved for 
treatment of ADHD and compulsive eating disorder (Blick and Keating, 2007; Hutson et 
al, 2014), and it was selected for initial testing because preclinical and clinical research 
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suggests that it might also be useful for treating cocaine use disorder (Banks et al, 
2015a; Mooney et al, 2015).  Furthermore, maintenance on its metabolite, d-
amphetamine, has been shown to decrease cocaine self-administration across a broad 
range of experimental conditions in rats, rhesus monkeys, human-laboratory studies, 
and placebo-controlled, double-blind clinical trials (Herin et al, 2010; Negus and 
Henningfield, 2015; Nuijten et al, 2016).  Each lisdexamfetamine dose was tested using 
a subchronic, 7-day treatment regimen, because medications to treat drug use 
disorders are administered chronically in humans, and it has been argued that 
preclinical animal- and human-laboratory studies should also evaluate effects of 
repeated treatment delivery to more accurately predict clinical effectiveness(Banks et al, 
2015b; Czoty et al, 2016; Haney and Spealman, 2008b; Mello and Negus, 1996). We 
hypothesized that 7-day treatment with lisdexamfetamine would produce a dose-
dependent decrease in cocaine choice and a reciprocal increase in choice of the food 
alternative in this concurrent independent progressive-ratio choice procedure.  
 
Methods 
Subjects. Studies were conducted in four adult male rhesus monkeys (Macaca 
mulatta). Two of the monkeys had a history of exposure to monoaminergic compounds 
(e.g. cocaine and amphetamine), and two had a history of exposure to mu opioid 
compounds (e.g. oxycodone and naloxone).   Each monkey had a surgically implanted 
venous catheter with a single lumen (Braintree Inc., Braintree, MA) or double lumen 
(STI Components, Roanoke, VA). Monkeys could earn 1g banana-flavored pellets 
(5TUR Grain-based Precision Primate Pellets; Test Diets, St. Louis, MO) during daily 
experimental sessions. In addition, monkeys received daily food rations (Lab Diet High 
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Fiber Monkey Biscuits; PMI Feeds, St. Louis, MO), and the biscuit ration size was 
individually determined for each monkey to maintain a healthy body weight. Biscuit 
rations were delivered in the afternoons after behavioral sessions to minimize the 
effects of biscuit availability and consumption on food-maintained operant responding. 
Animals also received fresh fruit 7 afternoons per week. Water was continuously 
available in each monkey’s home chamber, which also served as the experimental 
chamber. A 12h light/dark cycle was in effect (lights on from 0600 to 1800 h). 
Environmental enrichment (foraging devices, novel treats, movies and music) was also 
provided after behavioral sessions. Facilities were accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care. The Institutional Animal Care 
and Use Committee approved all experimental protocols. 
Apparatus. Each home cage was equipped with an operant response panel, 
which had two response levers with three stimulus lights above each lever. The lights 
over the left and right levers were white and red, respectively. Additionally, the cages 
were equipped with a pellet dispenser that delivered food pellets to a receptacle within 
the cage. The externalized section of the intravenous catheter for drug self-
administration was routed through a jacket and tether system (Lomir Biomedical, 
Quebec, Canada) to the rear of the cage and connected to a peristaltic fluid pump 
(Cole-Parmer, Chicago, IL). Catheter patency was periodically evaluated with 
intravenous (IV) ketamine (4 mg/kg) administration, and the catheter was considered 
patent if IV ketamine administration produced overt loss of muscle tone within 20 sec. 
Single Alternative Training. Initial training for food-maintained responding 
proceeded in a series of incremental steps, during which only one lever and associated 
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stimulus lights were active (the “food-associated lever,” counterbalanced between 
monkeys).  Under the terminal progressive-ratio (PR) schedule, daily 5 hr behavioral 
sessions consisted of 10 discrete 30-min trials. The first trial was a “sample” trial, in 
which subjects received non-contingent delivery of 10 pellets. The remaining 9 trials 
were “response” trials, in which food pellets were available under the PR schedule.  
Stimulus lights were illuminated over the lever at the start of each trial, and completion 
of the ratio requirement produced food pellet delivery, initiated a time out (TO) for the 
remainder of the trial, and incremented the ratio for the next trial. If a monkey failed to 
complete the ratio requirement within 30 min, the trial terminated without reinforcement, 
the response counter reset to “0,” a 1-min TO period ensued, and the ratio requirement 
did not increment for the next trial.  The starting ratio was 200 in 2 monkeys and 400 in 
the other 2 monkeys, and the increment after each completed ratio was 100 for all 
monkeys (i.e. PR values were 200, 300, 400…1000 for two monkeys; 400, 500, 
600…1200 for the other 2 monkeys).  The lower starting ratio was used in two monkeys 
because they failed to complete ≥8 trials with higher starting ratios.  Once monkeys 
reliably completed ≥8 trials for the 10-pellet reinforcer magnitude under the terminal 
schedule, a pellet magnitude-effect curve was determined at magnitudes of 0, 1, 3 and 
10 pellets.  During these studies, the designated pellet magnitude was delivered non-
contingently during the sample trial of each daily session, and responding under the PR 
schedule produced this pellet magnitude during subsequent response trials. Each pellet 
magnitude was presented for a minimum of 7 consecutive days and until responding 
stabilized (number of trials completed for the last 3 days within 1 of the running mean, 
with no increasing or decreasing trends). Responding maintained by 10 pellets was 
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determined first in all monkeys, and the remaining pellet magnitudes were studied in a 
mixed order across monkeys.  
Once the pellet magnitude-effect curve was completed, an intravenous catheter 
was surgically implanted using aseptic procedures, and cocaine training began. The 
training regimen for cocaine self-administration was identical to that for food-maintained 
responding with the exception that the other lever and associated stimulus lights were 
active (the “cocaine-associated lever”), and responding produced intravenous cocaine 
injections. Training proceeded until responding maintained by 0.43 mg/kg/injection 
cocaine was stable under the same terminal schedule used for food in that monkey (i.e. 
starting ratio of 200 in 2 monkeys and 400 in the other 2 monkeys, with an increment of 
100 in all monkeys). Subsequently, a cocaine dose-effect curve was determined at 
doses of 0, 0.043, 0.14 and 0.43 mg/kg/injection cocaine using test durations and 
stability criteria identical to those used for the pellet magnitude-effect curve.  The 
cocaine doses were selected to match approximate unit cocaine doses used in the 
parallel human-laboratory study (i.e. 0.043, 0.14 and 0.43 mg/kg/injection unit doses in 
monkeys are equivalent to doses of 3, 10 and 30 mg for a 70 kg human subject; Lile et 
al., 2016; see companion paper in this issue). Responding maintained by 0.43 
mg/kg/injection was determined first in all monkeys, and the remaining doses were 
studied in a mixed order across monkeys.    
Cocaine vs. Food Choice Procedure. After determination of magnitude-effect 
functions for food and cocaine alone, concurrent-choice studies were initiated to assess 
cocaine choice dose-effect curves during concurrent availability of 1, 3 or 10 pellets.  
Choice session were identical to sessions under the terminal schedule for food or 
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cocaine alone with the following exceptions: (1) a single pellet magnitude and a single 
cocaine dose were concurrently available, (2) both the food and drug reinforcers 
available during that session were delivered non-contingently at the start of the sample 
trial, with food delivered first, and cocaine delivered 5 min later, (3) both food- and 
cocaine-associated levers were active at the start of each choice trial, and lights above 
both levers were illuminated, (4) the first response during each trial locked in choice for 
that reinforcer during that trial, deactivated the alternative lever, and extinguished lights 
above the alternative lever, and (5) completion of a ratio produced the chosen reinforcer 
and incremented the ratio requirement only for that reinforcer in the next trial. If a 
monkey failed to complete a ratio requirement within 30 min, then the trial terminated 
without reinforcement, the response counter reset to “0” for both levers, a 1-min TO 
period ensued, the ratio did not increment for either reinforcer for the next trial, and the 
trial was counted as an “omission.” Each combination of pellet magnitude and cocaine 
dose was in effect for 7 consecutive days, and all cocaine doses were tested in 
combination with a single pellet magnitude before proceeding to a different pellet 
magnitude. Both the order of cocaine doses within a pellet magnitude and the order of 
pellet magnitudes were randomized across monkeys. 
 Effects of Lisdexamfetamine. Prior to testing lisdexamfetamine, choice 
performance was first re-established between 0.14 mg/kg/injection cocaine and 10 
pellets (see Results for rationale). Each lisdexamfetamine dose (0.32, 1.0, 1.8, and 3.2 
mg/kg/day) was tested for 7 consecutive days, and baseline choice performance was 
re-established over a period of at least 4 days between each 7-day lisdexamfetamine 
dose test. On test days, lisdexamfetamine was administered by slow IV infusion over a 
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period of 30 min beginning 1 h before the start of the daily choice session. The dose of 
1.8 mg/kg/day lisdexamfetamine fully suppressed responding in one of the four 
monkeys, and as a result, 3.2 mg/kg/day lisdexamfetamine was not tested in this 
subject. The order in which lisdexamphetamine doses were tested was randomized 
across monkeys. 
Data Analysis. The primary dependent variables were the mean numbers of 
cocaine choices, food choices, and omissions per session. Data from the last three 
days of each test condition were first averaged within a monkey and then averaged 
across monkeys to generate group means. Data were analyzed by one- or two-way 
repeated-measures ANOVA, as appropriate, and a significant ANOVA was followed by 
either a Dunnet’s or Holm-Sidak post hoc test. The criterion for significance was p<0.05.    
Drugs. ()-Cocaine HCl (NIDA, Rockville, MD) and lisdexamfetamine mesylate 
(B. E. Blough, Research Triangle Institute) were dissolved in sterile saline for IV 
injection.  
 
Results 
Responding maintained by food or cocaine alone. Training took an average 
of 2.5 months to reach the terminal schedule of food presentation (range = 43 - 142 
days). Food pellets maintained a magnitude-dependent increase in responding (Figure 
2-1A). When 0 pellets were available, subjects completed an average of approximately 
1 ratio requirement. As the number of pellets available increased, subjects increased 
the number of trials completed (F3,9 = 17.96, p < 0.001), such that an average of 
approximately 8 trials were completed when 10 pellets were available.  
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Cocaine self-administration training took an average of 34 days to reach the 
terminal schedule (range = 24 - 48 days), and cocaine also maintained a dose-
dependent increase in responding (Figure 2-1B). When saline was available, subjects 
completed an average of approximately 1 ratio requirement. As the dose of cocaine 
increased, the number of trials completed increased (F3,9 = 53.42, p < 0.0001), such 
that an average of at least 8 trials were completed during availability of 0.14 and 0.43 
mg/kg/injection cocaine. 
Choice between food and cocaine. Figure 2-2 shows the mean numbers of 
completed cocaine trials, completed food trials, and omissions during the final three 
days for each cocaine dose at each pellet magnitude.  Data within each panel were 
analyzed by two-way ANOVA [cocaine dose (0, 0.043, 0.14 and 0.43 mg/kg/injection) x 
trial outcome (cocaine choice, food choice, or omission)], and this analysis revealed a 
significant interaction at each pellet magnitude (Panel A: F6,18 = 9.03, p < 0.001; Panel 
B: F6,18 = 10.82, p < 0.0001; Panel C: F6,18 = 17.02, p < 0.0001).  Across all 3 pellet 
magnitudes, cocaine maintained a dose-dependent increase in the number of cocaine 
trials completed, and doses of 0.14 and 0.43 mg/kg/injection were always chosen in 
significantly more trials than saline, as denoted by asterisks over open bars in Figure 2-
2A-C.  Similarly, across all three pellet magnitudes, the mean number of food trials 
completed tended to decrease as cocaine dose increased; however, this trend was 
significant only during availability of 3 and 10 pellets. Under those conditions, the 
number of food choices was higher during concurrent availability of saline than during 
concurrent availability of 0.14 and 0.43 mg/kg/injection cocaine, as denoted by asterisks 
over closed bars in Figure 2-2B,C. Omissions tended to be highest when low 
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magnitudes of the food and cocaine reinforcers were concurrently available (e.g. during 
concurrent availability of 1 pellet and saline injections in Figure 2-2A), and the mean 
number of omissions tended to decrease as cocaine dose increased.  This tendency 
attained significance during the availability of 1 pellet, when the number of omissions 
was higher during availability of saline than during availability of 0.14 and 0.43 
mg/kg/injection cocaine, as denoted by asterisks over gray bars in Figure 2-2A).  
The analysis of choice results as shown in Figure 2-2 also permitted evaluation 
of preference between food and cocaine at each combination of pellet magnitude and 
cocaine dose (see dollar signs in Figure 2-2A-C).  Both 0.14 and 0.43 mg/kg/injection 
cocaine were preferred to 1 pellet (Figure 2-2A).  During availability of 3 pellets, food 
was preferred to saline injections, whereas 0.14 and 0.43 mg/kg/injection cocaine were 
preferred to food (Figure 2-2B).  During availability of 10 pellets, food was preferred to 
saline and the lowest dose of 0.043 mg/kg/injection cocaine, whereas the highest dose 
of 0.43 mg/kg/injection cocaine was preferred to food (Figure 2-2C).  During the 
availability 10 pellets, preference for the 0.14 mg/kg/injection cocaine dose was not 
significant. 
Effects of lisdexamfetamine treatment. Choice between 0.14 mg/kg/injection 
cocaine and 10 pellets was selected as the baseline for the experiment with 
lisdexamfetamine because (1) it yielded a trend albeit non-significant toward cocaine 
preference (approximately 6 cocaine and 3 food trials completed) with few omissions, 
and (2) a reduction in cocaine dose produced reallocation of choice that resulted in 
significant preference for this food magnitude, again with few omissions.  Thus, 
behavior maintained by this pair of reinforcer magnitudes was likely to be sensitive to 
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reductions in the relative reinforcing efficacy of cocaine during pharmacological 
treatment. As a prelude to presentation of lisdexamfetamine effects, Figure 2-3A shows 
four hypothetical changes in choice between 0.14 mg/kg/injection cocaine and 10 
pellets that could be observed during candidate medication treatment. Outcome #1 is 
interpreted as therapeutically desirable and consists of a decrease in cocaine trials 
completed with a reciprocal increase in food trials completed. This outcome indicates a 
reallocation of behavior from cocaine choice to food choice and a decrease in the 
relative reinforcing efficacy of cocaine in comparison to food.  Outcomes #2-4 show 
three other possible outcomes interpreted as therapeutically undesirable.  Specifically, 
outcome #2 shows a concurrent decrease in both cocaine and food trials with an 
increase in omissions, suggestive of non-selective behavioral suppression; outcome #3 
shows an increase in completed cocaine trials with a reciprocal decrease in food trials, 
suggestive of increased relative reinforcing efficacy of cocaine; and outcome #4 shows 
no treatment effect.  Of course, graded outcomes between these extremes are also 
possible.  
Figure 2-3B shows choice between 0.14 mg/kg/injection cocaine and 10 pellets 
during 7-day treatments with different lisdexamfetamine doses (0, 0.32, 1.0, 1.8, and 3.2 
mg/kg/day) Data were analyzed by two-way ANOVA (trial outcome x lisdexamfetamine 
dose), which revealed a significant interaction (F6,18 = 4.82, p < 0.01). Lisdexamfetamine 
doses of 0.32 and 1.0 mg/kg/day did not significantly alter cocaine or food trials 
completed or the number of omissions. A dose of 1.8 mg/kg/day lisdexamfetamine 
decreased cocaine trials completed, had no effect on completed food trials, and 
increased omissions. The high dose of 3.2 mg/kg/day lisdexamfetamine was tested in 
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only 3 monkeys and produced a profile of effects similar to 1.8 mg/kg/day 
lisdexamfetamine.  
Lisdexamfetamine time course effects are shown in Figure 4, and saline 
substitution effects are included for comparison. Under baseline conditions, preference 
between 0.14 mg/kg/day cocaine and 10 pellets was relatively stable across all 7 days 
(Figure 2-4A).  Saline substitution decreased the number of trials completed on the 
cocaine-associated key and produced a reciprocal increase in food trials completed.  
This reallocation of behavior was evident on day 1 and sustained throughout the 7-day 
experiment. (Figure 2-4B).  Lisdexamfetamine produced a dose-and time-dependent 
decrease in cocaine trials completed while having smaller and more transient effects on 
completed food trials. Thus, the decline in cocaine choice was associated with 
sustained food choice and an increase in trial omissions (Figure 2-4C-F).      
Individual subject data during 1.8 mg/kg/day lisdexamfetamine treatment are 
shown in Figure 2-5. This dose of lisdexamfetamine decreased the number of 
completed cocaine trials in all four monkeys, but the degree to which this decrease in 
cocaine choice was accompanied by a reciprocal increase in food choice varied across 
monkeys. Monkey 1501 showed the most robust behavioral reallocation from cocaine to 
food choice without an increase in omissions (Figure 2-5A). Monkeys 1498 and 1416 
showed smaller increases in food trials completed together with small increases in 
omissions (Figure 2-5B-C). Finally, in Monkey 1524, lisdexamfetamine decreased both 
cocaine and food trials completed together with an increase in omissions (Figure 2-5D).  
The lower dose of 1.0 mg/kg/day lisdexamfetamine produced little change in cocaine vs. 
food choice in this monkey. 
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Discussion 
The goal of this study was to develop a cocaine-vs.-food choice procedure in 
rhesus monkeys homologous to a cocaine-vs.-money procedure in humans as an 
experimental tool to facilitate translational research for the development of medications 
to treat cocaine use disorder (Lile et al, 2016).  There were three main findings. First, 
rhesus monkeys could be trained to choose between cocaine and food under a 
concurrent progressive-ratio schedule very similar to that used in humans to study 
choice between cocaine and money. Second, for rhesus monkeys as in humans, the 
allocation of behavior between cocaine and the alternative reinforcer varied 
systematically as a function of cocaine dose and magnitude of the alternative reinforcer. 
In particular, when the highest magnitude of 10 pellets was available as the alternative 
to cocaine in rhesus monkeys, there were few omissions, and preference for the 0.14 
mg/kg/injection cocaine dose was no longer significant. Lastly, repeated 7-day 
treatment with the candidate medication lisdexamfetamine produced a dose-and time-
dependent decrease in cocaine choice in all monkeys, and did not significantly impact 
food choice.  These results illustrate the use of the procedure to study a candidate 
medication and provide qualified support for further consideration of lisdexamfetamine 
maintenance to treat cocaine use disorder.    
 Choice between cocaine and food. This study extends the range of conditions 
under which cocaine-vs.-food choice has been established in rhesus monkeys (Foltin et 
al, 2015; Nader and Woolverton, 1991; Negus, 2003; Paronis et al, 2002; Woolverton 
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and Balster, 1981). Specifically, this study used a concurrent independent progressive-
ratio procedure to mimic drug-vs.-money choice procedures used previously in human 
laboratory studies in general (Jones and Comer, 2013; Moeller and Stoops, 2015; 
Stoops et al, 2012; Sullivan et al, 2006) and to match the cocaine-vs.-money choice 
procedure used in the companion human laboratory study in particular (Lile et al, 2016). 
As such, this study represents an example of back-translation, in which a procedure 
originally developed for use in humans was modified for use in laboratory animals. 
Back-translation is one approach that has been used in other disciplines to strengthen 
the procedural concordance between animal and human studies and improve the 
predictive power of forward animal-to-human translational research (Insel et al, 2013; 
Keeler and Robbins, 2011).  This approach of back-translation has also been 
recommended as a strategy to strengthen translational research on medications 
development for cocaine abuse (Czoty et al, 2016). To our knowledge, this is the first 
demonstration of cocaine vs. food choice by rhesus monkeys under this type of 
schedule, although both food and cocaine-maintained responding have been 
established separately under progressive-ratio schedules in rhesus monkeys(Bedford et 
al, 1978; Negus and Mello, 2003a; Rowlett et al, 1996; Stafford et al, 1999). 
Previous studies have demonstrated that choice between cocaine and food is 
sensitive to manipulation of both the cocaine dose and food-reinforcer magnitude in 
both rhesus monkeys (Nader and Woolverton, 1991; Negus, 2003) and rats (Thomsen 
et al, 2013).  In the present study, similar effects were obtained.  In general, increasing 
the magnitude of the available cocaine dose resulted in increased cocaine choice and 
decreased food choice, whereas increasing the magnitude of the food reinforcer 
 38 
 
increased food choice and decreased cocaine choice. The reciprocal effects of 
reinforcer magnitude on preference were especially apparent when cocaine dose was 
manipulated during concurrent availability of 10 pellets.  Under these conditions, 
increasing cocaine doses produced a systematic shift from robust food preference to 
robust cocaine preference, and omissions were rare. These results in the monkey 
cocaine-vs.-food choice procedure closely approximate the shift from money preference 
to cocaine preference produced by increasing cocaine doses in the human cocaine-vs.-
money choice procedure described in the companion manuscript (Lile et al, 2016). This 
concordance in results from monkey and human cocaine choice procedures provides 
one source of evidence to support utility of these homologous procedures for 
translational research on determinants of cocaine choice.  
  It is also notable that the dose-dependent increases in cocaine-vs.-food choice 
in rhesus monkeys observed here and in a previous study (Foltin et al, 2015) were 
obtained under discrete-trial procedures that limited the frequency of cocaine injections.  
These findings contrast with a recent report suggesting that cocaine vs. saccharin 
preference could be established in rats when intervals between choice opportunities 
were short (0 or 1 min) but not when inter-trial intervals were longer (10 min) (Vandaele 
et al, 2015).  The reasons for this discrepancy are not clear and may be related to 
various procedural differences including species and identity of the non-drug alternative 
reinforcer; however, in the present study using discrete 30-min trials, the highest 
cocaine dose (0.43 mg/kg/inj) was preferred to food at all food magnitude alternatives.     
 Effects of 7-day lisdexamfetamine treatment on cocaine vs. food choice.  
Results of the present study confirm and extend previous reports that cocaine vs. food 
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choice can be reduced by maintenance either on lisdexamfetamine in rhesus monkeys 
(Banks et al, 2015a) or on its primary metabolite amphetamine in rhesus monkeys or 
rats (Banks et al, 2013; Negus, 2003; Thomsen et al, 2013).  Amphetamine 
maintenance also decreased cocaine self-administration maintained under other, non-
choice schedules of reinforcement in rhesus monkeys and rats (Chiodo et al, 2008; 
Czoty et al, 2010; Negus and Mello, 2003a, 2003b), as well as cocaine choice in human 
laboratory studies and metrics of cocaine use in clinical trials (Grabowski et al, 2001; 
Levin et al, 2015; Nuijten et al, 2016; Rush et al, 2010; Stoops and Rush, 2013). The 
present proof-of-concept study used intravenous lisdexamfetamine to permit precise 
control of the administered dose, but lisdexamfetamine is formulated for oral 
administration in humans and would likely be tested using oral administration in human 
laboratory studies.  Future translational studies with candidate medications might 
benefit from use of the same route of administration for treatment drugs in monkeys and 
humans to parallel use of the same route of administration for cocaine.    
A recent double-blind, placebo-controlled pilot clinical trial found that 
lisdexamfetamine maintenance was not significantly better than placebo in reducing 
cocaine use by a group of 43 cocaine-dependent individuals (Mooney et al, 2015).  
However, four caveats warrant mention in comparing that clinical trial in humans to the 
present study in monkeys. First, subjective reports of craving were significantly reduced, 
and cocaine use was significantly reduced by lisdexamfetamine in a secondary analysis 
that examined the subset of patients that completed the 14-week study.  Thus, there 
was some evidence for modest effectiveness of the lisdexamfetamine doses tested.  
Second, the highest dose evaluated in that clinical trial was 70 mg/day, which is 
 40 
 
approximately equivalent to the dose of 1 mg/kg/day in monkeys.  Both 70 mg/day 
lisdexamfetamine in humans and 1 mg/kg/day lisdexamfetamine produced similar, small 
and non-significant decreases in metrics of cocaine use.  Thus, there was evidence for 
concordance in effects produced by similar lisdexamfetamine doses in humans and 
monkeys.   Third, the authors of the clinical trial appreciated the impact of regulatory 
constraints on the doses they could test, and they noted that “Evaluation of higher 
doses of lisdexamfetamine may provide clearer evidence of its efficacy in treating 
cocaine dependence.” Results of the present study illustrate how preclinical studies 
might be useful to inform decisions on whether to pursue testing of higher doses in 
humans.  Specifically, this study found that cocaine choice was significantly reduced by 
a higher dose of 1.8 mg/kg/day lisdexamfetamine in monkeys (equivalent to 126 mg/day 
in a 70 kg human), and this supports the speculation by the clinical trial authors that 
higher lisdexamfetamine doses might also be more effective to decrease cocaine use in 
humans. Lastly, the clinical trial revealed individual differences in some adverse events, 
in medication adherence, and in study retention. The present study also identified 
individual differences in undesirable lisdexamfetamine effects in monkeys. Specifically, 
although lisdexamfetamine significantly reduced choice of 0.14 mg/kg/inj cocaine doses 
in all subjects, the degree to which this decrease in cocaine choice was accompanied 
by a reciprocal increase in food choice varied across subjects. This variability in 
lisdexamfetamine effectiveness to promote behavioral reallocation to food choice 
observed in the present study may be related to the individual differences in the adverse 
effects of lisdexamfetamine in humans, which would further support the concordance 
between non-human primate data using these procedures and clinical trial results. 
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Taken together, the results of the present study with lisdexamfetamine illustrate one 
strategy for medication evaluation in this procedure.  These results provide a preclinical 
treatment profile that can be compared to results with other candidate medications as 
they are tested in the future.  In particular, it would be of interest to identify treatments 
that not only reduce cocaine choice, but that also produce a more robust and reliable 
reallocation of responding to food choice than was produced here by lisdexamfetamine.  
Additionally, these results provide an outcome in monkeys that could be directly 
compared to results obtained in the complementary cocaine-vs.-money choice 
procedure in humans.  A comparison of treatment effects with lisdexamfetamine and 
other candidate medications on cocaine choice in rhesus monkeys and humans will be 
important for continued validation and refinement of this platform for translational 
research. 
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Figure 2-1. Effects of reinforcer magnitude under the discrete trials progressive ratio 
procedure.  Abscissae: Reinforcer magnitude in units of pellet number (A) or cocaine 
dose (mg/kg/injection; B) available during each trial.  Ordinates: Number of trials 
completed.  Each condition was presented for a minimum of 7 days and until stable 
responding was observed. All points show mean±SEM for the final 3 days in 4 
monkeys. Asterisks (*) indicate statistical significance (p < 0.05) compared to 0 pellets 
(A) or saline (B).
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Figure 2-2. Trials completed for either cocaine or food when 1, 3 or 10 food pellets 
were available as the alternative to cocaine.  Abscissae: Unit dose of cocaine available 
during each trial (mg/kg/injection).  Ordinates: Number of cocaine and food trials 
completed, or number of omitted trials. Each combination of cocaine dose and pellet 
reinforcer magnitude was available for 7 days. All bars show mean ± SEM for the final 3 
days in 4 monkeys. Asterisks (*) indicate statistical significance (p < 0.05) within a trial 
outcome (cocaine choice, food choice, or omission) compared to the 0 cocaine data. 
Dollar signs ($) indicate statistical significance (p<0.05) within a cocaine dose between 
the numbers of cocaine vs. food trials completed.  
  
 44 
 
 
Figure 2-3. Treatment effects on choice between 0.14 mg/kg/injection cocaine and 10 
pellets. Abscissae: (A) Hypothetical treatment outcome # (see text for details) or (B) 
lisdexamfetamine dose (mg/kg/day). Ordinates: Number of cocaine and food trials 
completed, or number of omitted trials.  All bars in Panel A show hypothetical data, and 
all bars in Panel B show mean ± SEM for the final 3 days in 4 monkeys (0-1.8 
mg/kg/day lisdexamfetamine) or 3 monkeys (3.2 mg/kg/day lisdexamfetamine). 
Asterisks (*) indicate statistical significance (p < 0.05) within a trial outcome (cocaine 
choice, food choice, omission) compared to the 0 lisdexamfetamine treatment dose in 
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Panel B.  Dollar signs ($) indicate statistical significance (p<0.05) within a 
lisdexamfetamine dose between the numbers of cocaine vs. food trials completed.   
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Figure 2-4. Time course of choice between injections and 10 pellets under different 
experimental conditions.  Abscissae: Experimental condition day.  Ordinates: Number of 
cocaine and food trials completed, or number of omitted trials.  (A) Baseline choice 
between 0.14 mg/kg/injection cocaine and 10 pellets.  (B) Choice between saline and 
10 pellets.  (C-F) Choice between 0.14 mg/kg/injection cocaine and 10 pellets during 
treatment with increasing lisdexamfetamine doses (0.32-3.2 mg/kg/day).  All points 
show mean±SEM for 4 monkeys except Panel F, where N=3.     
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Figure 2-5.  Individual subject data for 0.14 mg/kg/injection cocaine and 10 pellets 
under baseline conditions and during 1.8 mg/kg/day lisdexamfetamine treatment.  
Abscissae: Treatment condition.  Ordinates: Number of cocaine and food trials 
completed, or number of omitted trials.  Graphs show data for individual subjects that 
contributed to mean data shown in Figure 2-3B, and all bars show mean ± SEM for the 
final 3 days in each subject.  The “x” symbol indicates no omissions under the indicated 
conditions.  
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Chapter III 
The Effects of Amphetamine Maintenance  
on Drug versus Food Choice in Rhesus Monkeys  
(In preparation for a joint manuscript with colleagues at the University of Kentucky) 
 
Introduction 
Amphetamine maintenance remains one of the only treatments to show 
consistent decreases in cocaine use in double-blind placebo controlled clinical trials 
(Grabowski et al, 2001, 2004a; Mariani et al, 2012). The results from the previous 
chapter indicated that the non-human primate choice procedure is sensitive to the 
amphetamine prodrug, lisdexamfetamine. In this experiment, we will test d-
amphetamine to continue the validation of the model and to be able to extend the 
findings to the parallel work being done at the University of Kentucky in the human self-
administration choice procedure. 
 
Methods 
Subjects. Studies were conducted in 3 adult male rhesus monkeys (Macaca 
mulatta) surgically implanted with a venous double-lumen catheter (0.03” ±0.01” inner 
diameter for each lumen; 0.093” ±0.014” total outer diameter; 0.011” wall diameter and 
70±5 durometer; Reiss Manufacturing, Inc, Blackstone, VA).  All 3 monkeys had 
responded in the cocaine-choice procedure for at least two years and been tested with 
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lisdexamfetamine as described previously (Johnson et al, 2016). Monkeys could earn 1 
g banana-flavored pellets (5TUR Grain-based Precision Primate Pellets; Test Diets, St. 
Louis, MO) during daily experimental sessions. In addition, monkeys received daily 
rations of fresh fruit and biscuits (Lab Diet High Fiber Monkey Biscuits; PMI Feeds, St. 
Louis, MO), and these rations were provided after behavioral sessions to minimize their 
impact on food-maintained responding. Environmental enrichment (foraging devices, 
novel treats, movies and music) was also provided after behavioral sessions. Water was 
continuously available in each monkey’s home chamber, which also served as the 
experimental chamber. A 12 h light/dark cycle was in effect (lights on from 0600 to 1800 
h). Facilities were accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care, and all procedures were approved by the Institutional Animal 
Care and Use Committee. 
Apparatus. Each home chamber was equipped with an operant response panel, 
which had 2 response levers and 3 stimulus lights above each lever. The lights over the 
left and right levers were white and red, respectively. Additionally, the cages were 
equipped with a pellet dispenser (ENV-203-1000, Med Associates, St. Albans, VT) that 
delivered food pellets to a receptacle within the chamber. The externalized section of 
the intravenous (IV) catheter was routed through a jacket and tether system (Lomir 
Biomedical, Quebec, Canada) to the rear of the chamber and connected to a peristaltic 
fluid pump (Cole-Parmer, Chicago, IL). Catheter patency was periodically evaluated 
with IV ketamine (4 mg/kg) administration, and the catheter was considered patent if IV 
ketamine administration produced overt loss of muscle tone within 20 s. 
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Choice sessions. Training was accomplished as described previously (Johnson 
et al, 2016). Under the terminal schedule, 5-hr choice sessions were conducted daily 
from 8:30am-1:40pm and consisted of 10 discrete 30-min trials separated by 1-min time 
out periods. During the first trial of each day, the unit cocaine dose (0.14 or 0.43 
mg/kg/injection, IV) and food reinforcer magnitude (10 pellets) available on that day 
were delivered non-contingently, with food delivered at the beginning of the trial and the 
unit cocaine dose administered 5 min later. The remaining 9 trials were response trials, 
during which cocaine and food pellets were available concurrently under independent 
progressive-ratio schedules. The starting ratio for both reinforcers was 200 in 2 
monkeys and 400 in the other monkey, and the increment after each completed ratio 
was 100 for all monkeys (i.e. PR values were 200, 300, 400…1000 for two monkeys; 
400, 500, 600…1200 for the other monkey).  Each response trial began with the 
stimulus lights illuminated over both the cocaine- and the food-associated levers, and 
both levers were active. The first response extinguished the stimulus lights over the 
alternative lever and locked in the choice for that trial. The subject had the remainder of 
the 30-min trial to complete the response requirement on the chosen lever, and 
responses on the alternative lever had no programmed consequence. Completion of the 
response requirement resulted in 1) extinguishing the stimulus lights over the lever, 2) 
delivery of the reinforcer, 3) incrementing the response requirement only for the chosen 
reinforcer, and 4) initiation of a TO for the remainder of the trial. If a monkey failed to 
complete a ratio requirement within 30 min, then the trial terminated without 
reinforcement, the response counter reset to “0” for both levers, a 1-min TO period 
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ensued, the ratio did not increment for either reinforcer for the next trial, and the trial 
was counted as an “omission.”   
Effects of d-amphetamine. Before starting tests with d-amphetamine, stable 
choice was established between 0.14 mg/kg/injection cocaine and 10 food pellets. 
These reinforcer magnitudes were selected based on our prior study (Johnson et al. 
2016). The criterion for stability was that the number of completed cocaine trials and 
omissions on each day was within 1 of the running 3-day mean, with no increasing or 
decreasing trends.  Each d-amphetamine dose (saline, 0.019, 0.037, 0.074 mg/kg/hr) 
was administered IV via continuous infusion 23 hours each day (4pm - 3pm next day) 
for 13 days through one lumen of the double-lumen catheter. The lower amphetamine 
doses were selected to match the doses tested in humans (0.019 and 0.037 mg/kg/hr = 
30 and 60 mg/day in a 70 kg human).  Additionally, to match the human testing 
regimen, the first 6 treatment days were designated as the acclimation period, and no 
behavioral sessions were conducted. For the remaining 7 treatment days, choice 
sessions were conducted to evaluate choice between 0.14 mg/kg/inj cocaine and 10 
pellets. Saline treatment conditions were reinstated for at least four days and until stable 
choice was reestablished before initiating the next treatment condition. d-Amphetamine 
dose order varied across monkeys. In addition, d-amphetamine (0.037 mg/kg/hr) 
treatment was also tested during choice between a higher unit cocaine dose (0.43 
mg/kg/injection) and 10 food pellets. For these studies, choice was evaluated using the 
13-day treatment protocol first for saline treatment and then for 0.037 mg/kg/hr 
amphetamine treatment. 
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Data analysis. The primary dependent variables were the mean numbers of 
completed cocaine trials and food trials per session.  Data for the last 3 days of each 
test condition were first averaged within a monkey and then averaged across monkeys 
to generate group means. Data were analyzed by two-way repeated-measures ANOVA 
with amphetamine dose and trial outcome (cocaine or food trials completed) as the two 
factors, and a significant ANOVA was followed by a Dunnett’s post-hoc test to compare 
choice during treatment with different amphetamine doses to choice during saline 
treatment.  Treatment effects on omissions were evaluated by a separate one-way 
ANOVA.  Individual and group data are also shown for all 7 days of choice testing 
during treatment with saline and 0.037 mg/kg/hr d-amphetamine.  The time course of 
group data were analyzed using a model comparison approach to evaluate the 
regression coefficient by an extra sum-of-squares F-test (Motulsky and Christopoulous 
2003).  For all statistical analyses, the criterion for significance was p<0.05.     
 
Plasma Amphetamine Analysis 
Specimen preparation and extraction. A freshly prepared seven-point 
calibration with a range of 10 ng/mL to 1000 ng/mL amphetamine (Cerilliant, Round 
Rock, TX), a drug-free control (negative control) containing only amphetamine-d11 
(Cerilliant, Round Rock, TX), the internal standard (ISTD), and a double negative 
control that contained neither amphetamine nor ISTD were analyzed with each batch of 
samples.  Amphetamine was extracted from the calibrators, controls, and samples using 
a previously described method for amphetamines, other phenylisopropylamines and 
their metabolites (Poklis and Moore, 1995).  Briefly, 50 µL (500 ng/mL amphetamine-
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d11) of the ISTD was added to 1.0 mL aliquots of calibrators, controls, and specimens, 
followed by 100 µL of concentrated ammonium hydroxide (Macron Fine Chemicals, 
Center Valley, PA) and 2.0 mL of n-butyl chloride (Burdick and Jackson, Muskegon, MI).  
Samples were mixed for 30 sec and centrifuged for 5 min. The n-butyl chloride layer 
was transferred to a borosilicate test tube (12 x 75 mm) and reduced to 1 mL under a 
gentle stream of nitrogen at room temperature. One hundred microliters (100µL) of 
heptafluorobutyric anhydride (Regis Technologies, Morton Grove, IL) was added to the 
mixture.  Samples were than heated at 70°C for 20 min. The n-butyl chloride was then 
evaporated under a gentle stream of nitrogen at room temperature and reconstituted in 
50 µL ethyl acetate (Fisher Scientific, Fairlawn, NJ). One microliter (1 µL) of the extract 
was injected into the Gas Chromatography Mass Spectrometry (GC/MS) for analysis. 
Gas chromatography mass spectrometry method. The identification and 
quantification of amphetamine was performed using a Shimadzu gas chromatography 
mass spectrometry QP-2010 with EI ionization (Shimadzu Scientific Inc., Columbia, 
MD).  Chromatographic separation was performed on an Rtx®-5 30m x 0.32mm, 0.5 µm 
capillary column (Restek Bellefonte, PA). The initial temperature was 70°C with a hold 
time of 1 min, then a 20°C/min ramp to 320°C and held for 0.5 min. The temperature for 
the injection port was 250°C; for the ion source 260°C; and for the interface 280°C.  The 
total flow rate was 42.1 mL/min with a column flow of 3.65 mL/min. The retention time 
for amphetamine was 3.89 min and for amphetamine-d11 3.68 min. The following ions 
were monitored for amphetamine, 240, 118 and 91 m/z and amphetamine-d11, 244 and 
128 m/z. Each calibrator concentration was determined to be within ±15% of the 
expected value. The linear regression correlation coefficients (r2) for all calibration 
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curves were ≥ 0.995. The amphetamine concentrations were determined by linear 
regression plot based on peak area ratio of the calibrators. 
Data analysis. Data from individual monkeys were averaged for each chronic 
amphetamine treatment dose. Plasma amphetamine levels were analyzed by one-way 
repeated-measures ANOVA with amphetamine dose as the factor, and a significant 
ANOVA was followed by a Bonferroni’s post-hoc test. 
Drugs. ()-Cocaine HCl (NIDA Drug Supply Program, Rockville, MD) and d-
amphetamine hemisulfate (Sigma Aldrich; St. Louis, MO) were dissolved in sterile water 
for IV injection. All drug doses are expressed as the salt forms listed above and all 
solutions were passed through a 0.2-m sterile filter (EMD Millipore, Billerica, MA) 
before IV administration.  
 
Results 
Effects of d-Amphetamine on cocaine vs. food choice. During saline 
treatment, monkeys completed a similar number of trials on the 0.14 mg/kg/injection 
cocaine- and 10-pellet food-associated levers (Figure 3-1). Also, monkeys rarely 
omitted a trial during saline treatment. d-Amphetamine dose-dependently (0.037 and 
0.074 mg/kg/hr) decreased the number of cocaine trials completed, and the largest d-
amphetamine treatment dose (0.074 mg/kg/hr) also significantly decreased the number 
of food trials completed [d-amphetamine dose: F3,6 = 12.69, p = 0.005; interaction: F3,6 = 
5.28, p = 0.04] (Figure 3-1). Increasing d-amphetamine treatment doses also tended to 
increase trial omissions, but the effect was not statistically significant [d-amphetamine 
dose: F1.19,2.37 = 12.69, p = 0.055]. Increasing the unit cocaine dose available to 0.43 
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mg/kg/injection as the alternative to 10 food pellets resulted in 4.6±0.6 and 1.9±1.2 trials 
completed on the cocaine- and food-associated levers, respectively (data not shown). 
Treatment with 0.037 mg/kg/hr d-amphetamine did not significantly alter cocaine 
(4.2±0.1) or food (1.6±1.1) trial completions compared to saline treatment conditions 
(data not shown, p>0.05).  
Figure 3-2 shows the time course of saline and 0.037 mg/kg/hr d-amphetamine 
treatment effects on cocaine and food trials completed in individual monkeys and for the 
group during concurrent availability of 0.14 mg/kg/injection cocaine and 10 food pellets.  
During 7-day saline treatment, the number of trials completed for each reinforcer was 
relatively stable in all monkeys, and the regression coefficients (95% CL) for group data 
did not differ from 0 for either cocaine (0.04; -0.16 to 0.23) or food choices (0.18; -0.02 
to 0.38), indicating no systematic changes in choice over time.  During 7-day 0.037 
mg/kg/hr d-amphetamine, cocaine but not food choice decreased in all monkeys.  For 
the group, the regression coefficient for cocaine was negative (-0.35; -0.59 to -0.1), 
indicating a significant decrease in cocaine choice over time, whereas the regression 
coefficient for food did not differ from 0 (0.04; -0.43 to 0.48). 
Mean (± SEM) plasma d-amphetamine levels at the end of 13-day d-
amphetamine treatments were 48.7 (±8.7) ng/mL for 0.019 mg/kg/hr d-amphetamine, 
128.7 (±30.3) ng/mL for 0.037 mg/kg/hr d-amphetamine, and 348 (±32.6) ng/mL for 
0.074 mg/kg/hr d-amphetamine. One-way ANOVA indicated a significant effect of 
amphetamine dose (F2,4 = 39.31, p = 0.002), and the post hoc test indicated that plasma 
amphetamine levels were higher during the 0.037 and 0.074 mg/kg/hr treatments as 
compared to the 0.019 mg/kg/hr d-amphetamine treatment. 
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Summary 
 Amphetamine maintenance decreased cocaine choices at 0.037 and 0.074 
mg/kg/hr. The highest dose, 0.074 mg/kg/hr, also decreased food choices. These 
results are consistent with results seen with amphetamine maintenance in preclinical 
choice procedures (Banks et al, 2013; Thomsen et al, 2013) and human laboratory 
choice procedures (Rush et al, 2010). Additionally, the amphetamine plasma levels 
provide a benchmark to which human amphetamine plasma levels can be compared. 
The amphetamine doses chosen for this study were equivalent to human doses in 
mg/kg/day of amphetamine exposure, but route of administration and the timing of the 
doses differ between species. The human subjects will be getting twice daily oral doses 
of amphetamine while the non-human primates received a continuous IV infusion 23 
hr/day, so comparison of plasma amphetamine levels will give more information about 
the equivalence of doses between the different dosing procedures. 
 I, along with the help of Katherine Nicholson, collected the amphetamine plasma 
samples from the monkeys, but did not analyze the samples for amphetamine 
concentration or learn the techniques associated with determining plasma amphetamine 
concentration. These analyses were performed by Justin Poklis. 
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Figure 3-1. Effects of saline or amphetamine treatment on cocaine vs. food choice by 
rhesus monkeys. Abscissa: amphetamine treatment dose in mg/kg/hr. Ordinate: 
Number of trials completed for 0.14 mg/kg/inj cocaine or for 10 food pellets. Number of 
omissions is also shown, and all bars show mean±SEM for the last three days of 
treatment in three monkeys. Asterisks indicate significantly different from “Saline” as 
determined by a significant two-way ANOVA followed by Dunnett’s post hoc test, 
p<0.05.  Note that “X” for cocaine choices during treatment with 0.074 mg/kg/hr 
amphetamine indicates that cocaine choices=0, and the bar is contained in the 
abscissa.    
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Figure 3-2. Time course of cocaine choice and food choice for individual monkeys and 
for the group during treatment with saline and 0.037 mg/kg/hr amphetamine.  The 
identification number for individual monkeys is shown in the upper left corner of each 
panel, and bottom panels show group data.  Abscissa: Days of amphetamine treatment.  
 59 
 
Note that that choice sessions were not conducted on Days 1-6 of treatment, so graphs 
show data only from Days 7-13.  Ordinate: Number of cocaine choices (left panels) or 
food choices (right panels) completed on each day  
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Chapter IV 
Amphetamine Maintenance Differentially Modulates Effects 
of Cocaine, Methylenedioxypyrovalerone (MDPV), and Methamphetamine 
on Intracranial Self-Stimulation and Nucleus Accumbens Dopamine Release 
in Rats  
(Submitted for publication) 
 
Introduction 
There are more than 2 million current (i.e. past month) psychostimulant users in 
the United States (SAMSHA, 2017), and no pharmacotherapies are currently approved 
by the Food and Drug Administration for treatment of psychostimulant abuse. According 
to the 2016 National Survey on Drug Use and Health (SAMSHA, 2017) cocaine and 
methamphetamine are the two most commonly abused psychostimulants, and other 
drugs such as methylenedioxypyrovalerone (MDPV) have emerged during the last 
decade that may also lead to problematic use (Karila et al, 2017). Many 
psychostimulants produce their effects by interacting with transporters for the 
monoamine neurotransmitters dopamine (DA), serotonin (5-HT), and norepinephrine 
(NE) (DAT, SERT, and NET, respectively) to increase synaptic monoamine levels, and 
drugs that are more potent to increase DA versus 5-HT tend to produce more robust 
abuse-related effects (Bauer et al, 2013; Rothman and Baumann, 2006; Suyama et al, 
2016; Wee et al, 2005). Moreover, there are 2 broad classifications of monamine 
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transporter ligands based on their transporter interactions. Uptake inhibitors like cocaine 
and MDPV bind to the transporters and inhibit their function and promote extracellular 
accumulation of the associated monoamine. Releasers like methamphetamine and 
amphetamine are shuttled through the transporters into cells, where they cause a 
cascade of events that results in monoamine efflux (De Felice et al, 2014; Rothman et 
al, 2001).  
Although no pharmacotherapies are approved to treat psychostimulant use 
disorders, amphetamine maintenance decreases cocaine use in double-blind placebo-
controlled clinical trials (Castelles et al, 2016; Grabowski et al, 2001; Greenwald et al, 
2010; Levin et al, 2015; Schmitz et al, 2012) and also decreases choice of cocaine over 
an alternative reinforcer in laboratory studies in humans, non-human primates, and rats 
(Banks et al, 2015a; Rush et al, 2010; Thomsen et al, 2013). In contrast, amphetamine 
maintenance is not effective to decrease methamphetamine use in either clinical trials 
or preclinical studies (Galloway et al, 2011; Schwienteck and Banks, 2015), and effects 
of amphetamine maintenance on abuse-related effects of other psychostimulants like 
MDPV are unknown. Additionally, the mechanisms that underlie selective 
amphetamine-maintenance effects on cocaine vs. methamphetamine use remain to be 
determined.  Amphetamine maintenance is thought to function as an agonist-type 
therapy for cocaine abuse because both drugs produce similar behavioral effects and 
increase synaptic DA levels in brain-reward areas such as nucleus accumbens (NAc) 
(Grabowski et al, 2004a; Rothman et al, 2002); however, it is not clear why such an 
agonist-type effect would be selective for cocaine but not methamphetamine.   
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Intracranial self-stimulation (ICSS) is one preclinical procedure that can be used 
to evaluate effects of candidate medications on abuse-related drug effects (Negus and 
Miller, 2014), and we reported previously that an amphetamine maintenance regimen 
sufficient to reduce cocaine-vs.-food choice in rats (Thomsen et al, 2013) also blunted 
cocaine-induced ICSS facilitation in rats (Bauer et al, 2014).  The present study 
extended this finding in three ways.  First, amphetamine-maintenance effects were 
compared on ICSS facilitation produced by cocaine, MDPV, and methamphetamine.  
Second, ICSS facilitation by monoamine transporter ligands correlates with selectivity to 
increase DA vs. 5-HT levels in NAc (Negus and Banks, 2017; Suyama et al, 2016).  
Accordingly, we also used in vivo microdialysis to compare amphetamine-maintenance 
effects on cocaine, MDPV, and methamphetamine-induced changes in NAc DA and 5-
HT levels.  We hypothesized that amphetamine maintenance would block effects of 
cocaine and the other DA uptake inhibitor MDPV, but not of the DA releaser 
methamphetamine, on both ICSS and NAc DA levels.  Lastly, effects of amphetamine 
maintenance on striatal DAT density were also determined, because DAT 
downregulation is one possible mechanism of amphetamine maintenance-induced 
decreases in cocaine effects (Boudanova et al, 2008; German et al, 2015).  
 
Methods 
Subjects 
Studies were conducted in a total of 119 male Sprague-Dawley rats, weighing 
300-350 grams at time of surgery. Rats were individually housed on a 12-hr light-dark 
cycle (lights on from 6 a.m.-6 p.m.) in a facility accredited by the Association for the 
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Assessment and Accreditation of Laboratory Animal Care. All rats had ad libitum access 
to food and water in their home cages. Animal maintenance accorded with The National 
Institutes of Health guidelines on care and use of research animals, and experimental 
protocols were approved by the Virginia Commonwealth University Institutional Animal 
Care and Use Committee. 
 
Surgical Procedures 
For implantation of microelectrodes and guide cannulae, subjects were 
anesthetized with 3.0-3.5% isoflurane in oxygen until unresponsive to toe-pinch and 
placed in a stereotaxic apparatus (Kopf Instruments, Tujunga, CA, USA). For ICSS 
studies, the cathode of a stainless steel electrode (0.25mm diameter and insulated 
except at the flattened tip; MS303/1-AIU/SPC, Plastics One, Roanoke, VA, USA) was 
implanted in the left medial forebrain bundle at the level of the lateral hypothalamus 
(2.8mm posterior to bregma, 1.7mm lateral to the midsagittal suture, and 8.8mm ventral 
to the skull). For microdialysis studies, guide cannulae (0.5mm outer diameter; CXG-8, 
Eicom, San Diego, CA, USA) were implanted bilaterally and terminated 1 mm above the 
nucleus accumbens (NAc; 1.5mm anterior to bregma, 1.8mm lateral to midsagittal 
suture, 6.0mm ventral to dura). A dummy cannula (CXD-8, Eicom) was inserted into 
each guide cannula to maintain cannula patency. Electrodes/guide cannulae were 
secured to the skull using screws (Plastics One, Inc., Roanoke, VA, USA) and 
orthodontic resin (Butler Schein, Dublin, OH, USA), and for ICSS studies, the anode of 
the electrode (0.125mm diameter, uninsulated) was wrapped around one of the screws 
to act as a ground.  Ketoprofen (5 mg/kg IP) was administered immediately after 
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surgery and again 24 hr later as a postoperative analgesic, and rats were allowed at 
least seven recovery days prior to initiation of ICSS training or microdialysis testing.  
For minipump implantation, rats were anesthetized with 3.0% isoflurane in 
oxygen until unresponsive to toe-pinch. An incision was made at the mid-scapular 
region and a subcutaneous pocket cleared. Osmotic minipumps (2ML2, Alzet, 
Cupertina, CA, USA) were inserted in the subcutaneous space, and the incision was 
sutured closed. Ketoprofen (5 mg/kg IP) was administered immediately after surgery as 
a postoperative analgesic. 
 
Intracranial Self-Stimulation (ICSS) 
Apparatus. Operant chambers consisted of sound-attenuating boxes containing 
modular acrylic and metal test chambers (29.2 × 30.5 × 24.1 cm). Each chamber had a 
response lever (4.5 cm wide, 2.0 cm deep, 3.0 cm off the floor), three stimulus lights 
(red, yellow, and green) centered 7.6 cm above the response lever, a 2 W house light, 
and an ICSS stimulator (Med Associates, St. Albans, VT, USA). Bipolar cables routed 
through a swivel-commutator connected the stimulator to the electrode (Model SL2C, 
Plastics One, Roanoke, VA, USA). Med-PC IV computer software controlled all 
programming parameters and data collection (Med Associates, St. Albans, VT, USA).  
Training. Training, testing, and data analysis was conducted using methods 
described previously (Bauer et al, 2013, 2014; Bonano et al, 2014; Pereira Do Carmo et 
al, 2009). Briefly, subjects were placed into operant chambers with the house light 
illuminated and allowed to press a lever to receive delivery of a 0.5-sec train of square-
wave cathodal pulses (0.1 msec/pulse) under a fixed-ratio (FR) 1 schedule of 
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reinforcement. Under the terminal schedule of reinforcement, daily behavioral sessions 
consisted of 3 10-min components, each consisting of 10 1-min trials. Each trial 
presented a different frequency of electrical stimulation available for brain stimulation, 
and the frequency decreased in 0.05 log increments across trials from 158-56 Hz.  The 
first 10 sec of each trial were a time out period, during which lever presses had no 
scheduled consequences and 5 non-contingent stimulations were delivered. The 
remaining 50 sec of each trial were a response period, during which lever presses 
produced brain stimulation and illumination of the stimulus lights over the lever under an 
FR 1 schedule of reinforcement. Training continued under these conditions until 
performance stabilized (3 days during which the mean numbers of stimulations per trial 
and total stimulations per component on each day were within 15% of the running mean 
across days). This was completed within 12 weeks of surgery for all rats, and the final 3 
days of training served to establish the “Pre-pump” baseline for ICSS performance. 
Testing. Once pre-pump baseline performance was established, testing was 
conducted using an 8-day treatment protocol.  On Days 0 and 7, rats received a series 
of increasing IP doses of cocaine (1, 3.2, 10 mg/kg), MDPV (0.1, 0.32, 1.0 mg/kg), or 
methamphetamine (0.1, 0.32, 1.0 mg/kg).  Dose-effect test sessions consisted of 3 
baseline ICSS components followed by 3 drug injections administered at 30-min 
intervals.  A pair of ICSS test components began 10 min after each injection.  Thus, 
dose-effect test sessions generated data for daily baseline performance and for effects 
produced by a 1-log-unit range of increasing test-drug doses.  On Day 1, after 
completion of the first dose-effect test session, rats were surgically implanted with 
osmotic minipumps containing either saline, 0.1 mg/kg/hr amphetamine, or 0.32 
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mg/kg/hr amphetamine, and 3-component baseline ICSS sessions were conducted on 
Days 2-6 before the second dose-effect test session on Day 7. Separate groups of N=6 
rats were used to test each minipump treatment in combination with each test drug, and 
only cocaine was tested with 0.1 mg/kg/hr amphetamine maintenance.    
Data Analysis. For all behavioral sessions, the first ICSS component on each 
day was considered a “warm-up” component, and data were discarded. The primary 
dependent measure for the remaining components of each session was rate of 
reinforcement as measured by number of stimulations in each trial. The raw 
reinforcement rate was normalized for each rat to a percent of maximum control rate 
(%MCR). The maximum control rate (MCR) was defined for each rat as the average of 
the maximal number of stimulations in any trial of the 2nd and 3rd components of the 3 
pre-pump baseline sessions. The number of stimulations for each trial during the 
remainder of the study was then converted to a percentage of the MCR using the 
equation %MCR = (reinforcement rate during a frequency trial / MCR) × 100.  Data for 
the 2nd and 3rd components of the 3 pre-pump baseline sessions were averaged first 
within each rat and then across rats to generate a group mean pre-pump baseline 
“frequency-rate” curve in each group to relate log frequency of brain stimulation to rate 
of reinforcement.  For dose-effect test sessions, data from the 2nd and 3rd daily-baseline 
components and for each pair of test components were averaged within each rat and 
then across rats to generate group mean frequency-rate curves for baseline and each 
test drug dose on that day.  Frequency-rate curves were compared in two ways.   First, 
repeated measures two-way ANOVA was used, with ICSS frequency as one factor and 
the experimental manipulation as the second factor. A significant ANOVA was followed 
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by Holm-Sidak post hoc test with the criterion for significance set at p < 0.05.  Second, 
the EF50 for each ICSS curve was deﬁned as the effective frequency that maintained 
50% MCR.  EF50 values and 95% confidence limits were interpolated by linear 
regression from the linear portion of each ICSS curve, and EF50 values were 
considered to be different if 95% confidence limits did not overlap.  In some cases, all 
points were above 50% MCR; in these cases, interpolation of EF50 values was not 
possible, and EF50 is shown as “<1.75” because 1.75 log Hz was the lowest frequency 
tested.  All analyses were conducted in Prism (Graphpad Software, La Jolla, CA).   
 
Microdialysis 
Procedure. Microdialysis procedures were similar to those described previously 
(Suyama et al., 2016). On test days, rats were briefly anesthetized with 3.0% isoflurane 
in oxygen, one of the dummy cannulae was removed, and a microdialysis probe (10mm 
long, CX-I-8-2, Eicom) with a 2mm artificial cellulose “cuprophan” membrane (50 kDa 
molecular weight cutoff) at its tip was inserted into an 8mm guide cannula such that it 
extended 2mm beyond the end of the guide cannula and into the NAc. The probe was 
connected to a two-channel liquid swivel (TCS2-23, Eicom), and the rat was placed into 
an acrylic experimental cage (30 cm3). Microdialysis probes were perfused with artificial 
cerebrospinal fluid (aCSF; 147 mM NaCl, 2.8mM KCl, 1.2mM CaCl2, 1.2mM MgCl2) at 
a rate of 1μL/min. Mobile phase consisted of 1.5% methanol (EMD, Gibbstown, NJ, 
USA), 100mM phosphate buffer (Sigma Chemicals, St. Louis, MO, USA), 500mg/L 1-
decane sodium sulfonate (TCI America, Montgomeryville, PA, USA), and 50 mg/L 
EDTA-2Na+ (Dojindo Laboratories, Kumamoto, Japan). Dialysate samples were 
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collected into a 50 μL injector loop at 10-min intervals using an online auto-injector 
(EAS-20s, Eicom) and immediately analyzed for DA and 5-HT concentrations by high-
performance liquid chromatography (HPLC) coupled to electrochemical detection 
(HTEC-500, Eicom). DA and 5HT were separated using a C18-reverse phase column 
(PP-ODS II, Eicom) and detected using a graphite working electrode and an Ag vs. 
AgCl reference electrode with an applied potential of +450 mV. DA and 5-HT were 
identified by characteristic standard solution retention times, and concentrations were 
quantified by comparison with peak heights of the standard concentration curve (0.01–
100 pg per 10 μL) generated prior to drug administration in each microdialysis 
experiment. The lower neurotransmitter detection limit was 0.1 pg.  
Baseline samples were collected until DA and 5-HT levels stabilized (six 
consecutive baseline samples with <25% variability around the running mean of both 
neurotransmitters).  Subsequently, a test drug dose was administered IP, and dialysate 
samples were collected for another 100 min. Two sets of studies were conducted.  First 
to determine the dose-dependence of test-drug effects, saline and multiple doses of 
cocaine (1.0, 3.2, 10 mg/kg), MDPV (0.1, 0.32, 1.0 mg/kg), or methamphetamine (0.1, 
0.32, 1.0 mg/kg) were evaluated in rats without a minipump.  Each rat was tested no 
more than four times (no more than twice per cannula; at least one week between re-
accessing a given site), and each dose of each drug was tested in 6 rats.  Second, to 
determine effects of amphetamine maintenance on test-drug effects, rats were 
surgically implanted with a minipump containing either saline or 0.32 mg/kg/hr 
amphetamine and tested between 7 and 13 days after minipump implantation with 
either 10 mg/kg cocaine, 0.32 mg/kg MDPV, or 0.32 mg/kg methamphetamine.  Each 
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minipump treatment and test drug group contained 6 rats.  The test-drug doses were 
selected because they were each found to produce similar, approximately 200-250% 
increases in NAc DA levels during initial dose-effect studies.  Some flexibility was 
instituted in the time of testing relative to minipump implantation to accommodate the 
occasional need for HPLC equipment repairs, but testing always occurred after at least 
7 days (the treatment duration in behavioral studies) and no more than 14 days (the 
maximum duration of minipump drug delivery).   
Data Analysis. The primary dependent variables were extracellular DA and 5-HT 
concentrations in each dialysate fraction. For dose-effect studies, data were expressed 
as a percentage of the baseline concentration for each neurotransmitter using the 
equation % Baseline = (test concentration / baseline concentration) * 100. For minipump 
studies, data were expressed as a difference (delta) from baseline (test concentration – 
baseline concentration) and absolute monoamine concentration in each sample.  A 
different approach was used for these studies because saline- and amphetamine-
treated rats had significantly different baseline DA levels prior to test-drug administration 
(see Results). Regardless of the metric, data at each time point were averaged across 
rats to yield group mean results. Results were analyzed for each drug dose using a 
repeated-measures one-way ANOVA, with time as a fixed effect and subject as a 
random effect (JMP Pro 11, SAS, Cary, NC). A significant ANOVA was followed by 
Dunnett’s post hoc test to compare monoamine concentrations at each time point with 
control monoamine concentrations in the sample evaluated 10 min after drug 
administration. This sample was selected as the control because preliminary 
experiments conducted by probe immersion into a known standard DA concentration 
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indicated a lag time of ~20min for dialysate to traverse the tubing from the probe to the 
electrochemical detector at the 1 μL/min flow rate.  Accordingly, the 10-min sample was 
collected prior to drug administration, had advanced into the auto-injector tubing at the 
time of drug injection, and was evaluated after drug injection.  Baseline DA and 5-HT 
levels in saline-treated and amphetamine-treated rats were compared by Student's t-
test with Welch’s correction. The criterion for statistical significance was set at p < 0.05.  
 
[3H]WIN35,428 Saturation Binding 
Membrane preparation.  Rats that had received no other surgeries or 
treatments were implanted with minipumps that delivered either saline (N=6) or 0.32 
mg/kg/hr amphetamine (N=8).  After 7 days of treatment, rats were euthanized by rapid 
decapitation, and whole striatum, including NAc and caudate/putamen, were dissected 
on ice and frozen at -80°C until use.  On the day of each binding assay, striata were 
thawed in cold assay buffer (20 mM sodium phosphate buffer, pH 7.9 with 0.32 M 
sucrose), homogenized with a Polytron homogenizer, and centrifuged at 50,000 x g at 
4°C for 10 min.  The supernatant was discarded, the pellet was re-suspended by 
homogenization in assay buffer, and the protein concentration was determined by the 
Bradford method. 
Binding assay.  The DA transporter inhibitors WIN35,428 [(–)-2β-carbomethoxy-
3β-(4-fluorophenyl)tropane] and RTI-112 [2β-carbomethoxy-3β-(3-methyl-4-
chlorophenyl)tropane] were used as the radiolabeled and non-labeled ligands, 
respectively(Kuhar et al, 1999). Six concentrations of [3H]WIN35,428, ranging from 
approximately 0.4-30 nM, were incubated in assay buffer containing 40 µg membrane 
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protein for 90 min at 30°C in a final volume of 0.25 ml.  Non-specific binding was 
determined at each concentration of radioligand in the presence of 30 µM unlabeled 
RTI-112.  The incubation was terminated by rapid filtration under vacuum through GF/B 
glass fiber filters using a 48-well Brandel harvester and rinsed 3 x with 3 ml ice-cold 50 
mM Tris-HCl, pH 7.4.  Bound radioactivity was determined by liquid scintillation 
spectrophotometry at 45% efficiency for 3H after overnight equilibration of the filters in 
Econosafe scintillation fluid. 
Data analysis.  All binding data are reported as specific binding, derived from 
duplicate determinations from the 6 saline-treated and 8 amphetamine-treated rats.  
Single-site saturation analysis (nH = 1) was conducted to determine Bmax and KD values 
by iterative curve fitting.  Bmax and KD values were compared between groups with the 
two-tailed unpaired Student’s t-test.  All analyses were conducted in Prism. 
 
Drugs 
For behavioral and microdialysis studies, (-) cocaine HCl, (±) 3,4-
methylenedioxypyrovalerone HCl, and (+)-amphetamine hemisulfate were obtained 
from National Institute for Drug Abuse drug supply program (Bethesda, MD, USA). (+)-
Methamphetamine HCl was obtained from Sigma Chemical Co. (St. Louis, MO, USA). 
All drugs were dissolved in bacteriostatic saline. Cocaine, MDPV, and 
methamphetamine were all administered via intraperitoneal injection at a volume of 1 
ml/kg. Amphetamine was delivered subcutaneously via an osmotic minipump (Alzet) at 
a rate of 5 µl/hr. 
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For receptor binding studies, [3H]WIN35,428 (82.6 Ci/mmol) was purchased from 
Perkin-Elmer (Waltham, MA).  RTI-112 was kindly provided by Dr. F. Ivy Carroll of 
Research Triangle Institute (Research Triangle Park, NC).  Econosafe scintillation fluid 
was purchased from Research Products International (Prospect IL). All other chemicals 
were reagent grade and purchased from Sigma Chemical Co. or Fisher Scientific 
(Hampton, NH). 
 
Results  
Intracranial Self-Stimulation 
Pre-pump baseline performance. Subjects were assigned to one of 7 groups 
(N=6 per group): cocaine + saline, 0.1 mg/kg/hr or 0.32 mg/kg/hr amphetamine; MDPV 
+ saline or 0.32 mg/kg/hr amphetamine; or methamphetamine + saline or 0.32 mg/kg/hr 
amphetamine. During pre-pump baseline sessions for all rats in the study, the mean ± 
S.E.M. maximum control rate (MCR) was 55.06 ± 1.5 reinforcements per trial and the 
mean EF50 (95% confidence limits) was 2.02 (2.00-2.03) log Hz. One-way ANOVA 
indicated no difference in MCRs across treatment groups (F(6,35) = 1.35, n.s.), and 
overlapping confidence limits indicated no difference in pre-pump baseline EF50 values 
across groups (Table 4-1). 
Pre-pump effects of cocaine, MDPV, and methamphetamine. Figure 4-1 and 
Table 4-1 show the effect of cocaine (1.0 – 10.0 mg/kg), MDPV (0.1 – 1.0 mg/kg), and 
methamphetamine (0.1 – 1.0 mg/kg) on Day 0, before minipumps were implanted.  Data 
are combined for saline- and amphetamine-treated rats because these data were 
collected before minipumps were implanted and before treatments had started. Brain 
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stimulation maintained a frequency-dependent increase in reinforcement rates under 
baseline conditions, and all three drugs produced dose-dependent leftward/upward 
shifts in ICSS frequency-rate curves (see figure legends for statistical results). The 
largest dose of 1.0 mg/kg methamphetamine also decreased high ICSS rates at the 
highest 2 frequencies. Table 4-1 shows that all 3 drugs also produced dose-dependent 
decreases in EF50 values.  EF50 values could not be determined for the highest doses 
of MDPV and methamphetamine, because facilitation was so robust that all points on 
the frequency-rate curves were above 50% MCR.   
Effects of saline or amphetamine maintenance on baseline ICSS.  Figure 4-2 
shows the effects of saline or 0.32 mg/kg/hr amphetamine maintenance on baseline 
ICSS. In saline-treated rats, the Day 8 baseline frequency-rate curves were not different 
from the pre-pump baseline in any group.  Conversely, 0.32 mg/kg/hr amphetamine 
maintenance facilitated ICSS in all 3 groups.  Additionally, Table 4-1 shows that EF50 
values in saline-treated rats were similar to pre-pump baselines; however, 0.32 
mg/kg/hr amphetamine produced EF50 values lower than pre-pump baselines and 
lower than baselines in saline-treated rats.  Figure 4-4 shows that a lower maintenance 
dose of 0.1 mg/kg/hr amphetamine also significantly facilitated ICSS in rats that were 
subsequently treated with cocaine.  
Effects of cocaine, MDPV, and methamphetamine during saline or 
amphetamine maintenance.  Figure 4-3 shows effects of cocaine, MDPV, and 
methamphetamine in rats treated with saline or 0.32 mg/kg/hr amphetamine, and EF50 
values are shown in Table 4-1.  Effects of all three drugs during saline maintenance 
were similar to pre-pump effects. Amphetamine maintenance produced an 
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approximately 10-fold decrease in the potency of cocaine to facilitate ICSS. Thus, 
during saline treatment, cocaine dose-dependently facilitated ICSS at all three doses as 
indicated both by two-way ANOVA of frequency-rate data (Figure 4-3) and by 
reductions in EF50 values (Table 4-1).  However, during maintenance on 0.32 mg/kg/hr 
amphetamine, there was only a main effect of cocaine dose and not a frequency x dose 
interaction. Post-hoc tests revealed that 10 mg/kg cocaine was different than baseline 
(see figure 4-3 legend for statistics).  Moreover, only 10 mg/kg cocaine significantly 
reduced EF50 values.  Figure 4-4 and Table 4-1 shows that maintenance on a lower 
amphetamine dose (0.1 mg/kg/hr) failed to blunt cocaine-induced ICSS facilitation. 
Maintenance on 0.32 mg/kg/hr amphetamine had lesser effects on MDPV-
induced ICSS facilitation.  In saline-treated rats, the lowest dose of 0.1 mg/kg MDPV 
significantly increased ICSS at only one frequency (1.95 log Hz) and failed to alter the 
EF50.  Higher doses of 0.32 and 1.0 mg/kg MDPV produced robust ICSS facilitation 
across a broad range of frequencies and also significantly reduced EF50 values.  In rats 
treated with 0.32 mg/kg/hr amphetamine, 0.1 mg/kg MDPV did not facilitate ICSS at any 
frequency or reduce the EF50, but higher doses still facilitated ICSS by both measures.  
Amphetamine maintenance also had only modest effects on methamphetamine-
induced ICSS facilitation.  In saline-treated rats, all methamphetamine doses facilitated 
ICSS both by two-way ANOVA of frequency-rate data and by significant reductions in 
EF50 values.  In rats treated with 0.32 mg/kg/hr amphetamine, the lowest dose of 0.1 
mg/kg methamphetamine no longer facilitated ICSS by analysis of frequency-rate 
curves, but this dose did still produce a significant, if small, decrease in EF50 value.  
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Moreover, higher doses of 0.32 and 1.0 mg/kg methamphetamine produced robust 
ICSS facilitation by both measures.       
 
 
Microdialysis 
Effects of cocaine, MDPV, and methamphetamine in rats without 
minipumps. Figure 4-8 shows that all microdialysis probe placements were in the NAc.  
Figure 4-5 shows the effects of saline, cocaine, MDPV and methamphetamine on NAc 
DA and 5-HT levels. Baseline DA and 5-HT levels were 1.46±0.09 and 0.27±0.01 
pg/9uL, respectively. After saline injection, DA levels did not significantly change, but 5-
HT levels increased slightly at 30 min to 109% of baseline (statistics shown in figure 
legend). Cocaine produced a dose- and time-dependent increase in both DA and 5-HT 
levels. 10 mg/kg cocaine increased DA levels across the entire dose range up to a 
maximum of 233% of baseline after 60 min, and increased 5-HT levels across the same 
dose range to a maximum of 284% of baseline after 40 min.  MDPV produced a dose-
and time-dependent increase in DA across the entire dose range but no increase in 5-
HT at any dose tested. The 0.32 mg/kg MDPV dose used for subsequent studies 
increased DA levels to a maximum of 201% of baseline after 100 min.  
Methamphetamine, like cocaine, produced a dose- and time-dependent increase in DA 
across the entire dose range and also increased 5-HT levels, but only at the highest 2 
doses tested. The 0.32 mg/kg methamphetamine dose used for subsequent studies 
increased DA levels to a maximum of 238% of baseline after 50 min, and 5-HT levels to 
a maximum of 147% of baseline after 30 min.     
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 Effects of saline or amphetamine maintenance on baseline DA and 5-HT 
levels.  Mean ± SEM DA levels in the NAc were increased by 7 days of 0.32 mg/kg/hr 
amphetamine treatment (9.28 ± 0.75 pg/9µL) as compared to 7 days of saline treatment 
(1.67 ± 0.52 pg/9 µL; t(17.26) = 7.68, p < .001). Conversely, mean ± SEM 5-HT levels in 
the NAc were similar in amphetamine-treated rats (0.38 ± 0.08 pg/9µL) as compared to 
the saline-treated rats (0.28 ± 0.06 pg/9 µL; t(28.04) = 1.69, n.s.). 
Effects of cocaine, MDPV, and methamphetamine during saline or 
amphetamine maintenance.  Figure 4-6 shows the effects of cocaine, MDPV, and 
methamphetamine on NAc DA and 5-HT levels after 7 treatment days with saline or 
0.32 mg/kg/hr amphetamine. Data are expressed as change from baseline (delta) rather 
than % baseline due to the significant difference in DA baselines between the groups. 
These data are also graphed as absolute concentrations in Figure 4-7 to show the 
differences in DA baseline and the effects of drugs relative to those altered baselines. 
Cocaine (10 mg/kg) significantly increased NAc DA levels after saline treatment 
but not after 7 days of 0.32 mg/kg/hr amphetamine treatment. Conversely, 10 mg/kg 
cocaine increased 5-HT levels in both saline- and amphetamine-treated rats. Thus, 
amphetamine maintenance selectively blocked cocaine-induced increases in NAc DA. 
MDPV (0.32 mg/kg) also significantly increased NAc DA levels in saline-treated rats but 
not in amphetamine-treated rats. MDPV did not significantly alter 5-HT levels in either 
saline- or amphetamine-treated rats. Thus, amphetamine maintenance also blocked 
MDPV-induced increases in NAc DA.  Methamphetamine (0.32 mg/kg) increased NAc 
DA and 5-HT levels in both saline- and amphetamine-treated rats. Thus, 
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methamphetamine failed to block methamphetamine-induced increases in NAc DA and 
5-HT. 
 
[3H]WIN35,428 Saturation Binding 
Mean ± SEM Bmax values in rats maintained on saline or 0.32 mg/kg/hr 
amphetamine were 1.52 ± 1.4 pmol/mg and 1.37 ± 0.04 pmol/mg of membrane protein, 
respectively.  Mean ± SEM KD values in rats maintained on saline or 0.32 mg/kg/hr 
amphetamine were 14.5 ± 1.8 nM and 14.9 ± 1.5 nM, respectively.  Neither the Bmax nor 
KD values differed significantly between the two groups, indicating that amphetamine 
maintenance at this dose did not affect striatal DAT levels or binding affinity for this 
radioliagand.    
Discussion  
 This study compared effects of amphetamine maintenance on abuse-related 
behavioral and neurochemical effects of cocaine, MDPV, and methamphetamine in rats.  
There were three main findings. First, cocaine, MDPV, and methamphetamine all 
produced dose-dependent increases in ICSS facilitation and NAc DA levels before 
treatment, although only cocaine and methamphetamine increased NAc 5HT levels. 
This is consistent with the previously published effects of these compounds in ICSS 
(Bauer et al, 2013, 2014; Bonano et al, 2014) and in microdialysis (Andrews and Lucki, 
2001; Baumann et al, 2012; Schindler et al, 2016). Second, on day 7 of amphetamine 
maintenance both baseline ICSS and NAc DA levels were elevated, but there was no 
significant change in baseline 5HT levels or in the density or binding affinity of striatal 
DAT. Finally, amphetamine maintenance blunted the effects of cocaine on both ICSS 
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and NAc DA levels while having little effect on methamphetamine-induced increases in 
ICSS or NAc DA. Conversely, amphetamine maintenance did not block effects of either 
cocaine or methamphetamine on NAc 5HT levels, and for MDPV, amphetamine 
maintenance had little effect on ICSS facilitation, but did block increases in NAc DA. 
Taken together, these results are consistent with the conclusion that amphetamine 
maintenance attenuates abuse-related behavioral effects of cocaine by reducing 
cocaine effects on NAc DA while conserving cocaine effects on NAc 5HT.  These 
results also suggest that amphetamine maintenance might be more effective as a 
pharmacotherapy for cocaine abuse than for MDPV or methamphetamine abuse.  
 The increase in ICSS baseline during amphetamine maintenance replicated 
findings from a previous publication (Bauer et al, 2014). The increase in baseline NAc 
DA levels, but not 5-HT levels) during amphetamine maintenance is also consistent with 
the idea that the behavioral effects seen in ICSS may reflect DA-system functioning, 
and are also consistent with the in vitro selectivity profile of amphetamine as a substrate 
for DAT>SERT (Rothman et al, 2001) and the in vivo selectivity e of acute amphetamine 
to increase NAc DA but not 5-HT (Suyama et al, 2016).  
 The effectiveness of 0.32 mg/kg/hr amphetamine to blunt ICSS facilitation by 10 
mg/kg cocaine also replicated findings from a previous study (Bauer et al, 2014). This 
study expands on the cocaine dose range tested in the previous data, showing that 0.32 
mg/kg/hr amphetamine is effective to block ICSS facilitation caused by lower cocaine 
doses and produce an approximate 10-fold rightward shift in the cocaine dose-effect 
curve for ICSS facilitation. These effects are consistent with decreased choice of 
cocaine during amphetamine maintenance in laboratory choice studies in humans, 
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monkeys and rats (Banks et al, 2015a; Rush et al, 2010; Thomsen et al, 2013). The 
microdialysis data reflect the ICSS data in that the abuse-related effect of cocaine, the 
NAc DA-increasing effect of 10 mg/kg, is abolished during amphetamine maintenance, 
while the 5-HT-increasing effect of cocaine is preserved. Selective 5-HT uptake 
inhibitors do not facilitate ICSS (Rosenberg et al, 2013) nor are they self-administered 
(Roberts et al, 1999).  
Amphetamine maintenance is less effective to blunt ICSS facilitation by 0.32 or 1 
mg/kg methamphetamine than cocaine. This is consistent with the clinical and self-
administration data on amphetamine maintenance for methamphetamine use, which 
suggests that amphetamine is not an effective pharmacotherapy for decreasing 
methamphetamine use (Galloway et al, 2011; Pike et al, 2014; Schwienteck and Banks, 
2015). The effect of amphetamine maintenance on NAc DA-increasing effect 
methamphetamine matches the effect seen in the ICSS experiment in that 0.32 mg/kg 
methamphetamine increased NAc DA and 5-HT levels during 0.32 mg/kg/hr 
amphetamine treatment. This effect is also consistent with increases in NAc DA versus 
5-HT levels reflecting both ICSS facilitation and self-administration of methamphetamine 
during amphetamine maintenance.  
In the ICSS experiment, amphetamine maintenance did not block the effects of 
0.32 or 1 mg/kg MDPV. This profile reflects the effects seen with methamphetamine in 
ICSS and suggests that amphetamine maintenance would be unlikely to be effective to 
decrease MDPV use in the clinic. The effect of amphetamine maintenance on the NAc 
DA-increasing effect of MDPV is similar to the effect of amphetamine maintenance on 
cocaine. Amphetamine maintenance blocks the DA increase after an injection of 0.32 
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mg/kg MDPV; however, MDPV lacks the 5-HT increasing effects of cocaine, potentially 
providing an explanation for the different effect of amphetamine maintenance on the 
abuse-related behavioral effects of cocaine and MDPV. These data suggest that 
blocking the DA increase caused by MDPV is not sufficient to block the abuse-related 
effects of this drug. Additionally, these data suggest that retaining the 5-HT-increasing 
effect of cocaine may be an important factor in the effectiveness of amphetamine 
maintenance for the treatment of cocaine use disorder. More studies are needed to 
determine the role of 5-HT in pharmacotherapy effects for MDPV and cocaine, because 
these drugs also differ in binding affinity at DAT and time course, both of which are 
factors that could play a role in the effects of a potential pharmacotherapy. 
Effects of amphetamine maintenance on DAT density were evaluated because 
some evidence suggests that amphetamine can reduce DAT function at least in part by 
promoting DAT internalization and downregulation. However, previous studies have 
found that in vivo amphetamine treatments sufficient to reduce DAT function did not 
reduce DAT expression (German et al, 2015). The present study extends on these 
findings by showing that a regimen of amphetamine maintenance sufficient to reduce 
abuse-related cocaine effects also did not reduce DAT density.  These results suggest 
that amphetamine maintenance does not reduce abuse-related cocaine effects by 
reducing DAT density, although DAT function may be suppressed despite sustained 
DAT expression. 
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Table 4-1.  EF50 values (95% confidence limits) in log Hz after administration of 
cocaine, MDPV, or methamphetamine in rats treated chronically with either saline or 
0.32 mg/kg/hr amphetamine.  * indicates significantly different from baseline as 
determined by non-overlapping confidence limits.  † indicates all points >50% MCR, and 
EF50 could not be calculated.  This outcome was also considered to be significantly 
different from baseline. 
 
  Dose 
Drug  (mg/kg) Prepump  Saline   Amphetamine 
 
Cocaine Baseline 2.02 (1.99-2.05)  2.02 (2.02-2.03)   1.90 (1.88-1.92) 
  1.0  1.93 (1.91-1.94)*   1.96 (1.93-1.99)*   1.87 (1.83-1.90) 
  3.2  1.89 (1.88-1.90)*   1.88 (1.83-1.92)*   1.91 (1.88-1.93) 
  10  1.75 (1.49-1.80)*   1.77 (1.57-1.83)*   1.83 (1.82-1.84)* 
 
MDPV  Baseline 2.02 (1.97-2.06)   2.01 (2.01-2.02)   1.86 (1.80-1.89) 
  0.1  1.97 (1.96-1.99)   1.98 (1.94-2.02)   1.84 (1.76-1.89) 
  0.32  1.80 (1.78-1.82)*   <1.75†    <1.75† 
  1.0  <1.75†    <1.75†    <1.75† 
 
 
Metham- Baseline 2.01 (1.99-2.04)   2.03 (2.00-2.05)   1.92 (1.91-1.94) 
phetamine 0.1  1.95 (1.94-1.95)*   1.93 (1.92-1.94)*   1.89 (1.88-1.90)* 
  0.32  1.83 (1.82-1.83)*   1.83 (1.78-1.87)*   1.77 (1.75-1.79)* 
  1.0  <1.75†     <1.75†    <1.75† 
 
 
 82 
 
 
Figure 4-1. Effects of cocaine (A, n=18), MDPV (B, n=12), and methamphetamine (C, 
n=12) on ICSS before minipumps were implanted.  Abscissae: Brain stimulation 
frequency in log Hz.  Ordinates: % Maximum control rate.  All points show mean±SEM, 
and filled points indicate significantly different from “Baseline” as determined by 2-way 
ANOVA followed by the Holm-Sidak post hoc test (p < 0.05).  For each panel, 2-way 
ANOVA indicated significant main effects of frequency and dose and a significant 
interaction.  Interaction results for each panel are as follows: (A) cocaine (F(27,459) = 
15.28, p < 0.0001), (B) MDPV (F(27,297) = 12.4, p < 0.0001), and (C) methamphetamine 
(F(27,297) = 20.62, p < 0.0001).   
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Figure 4-2. Effects of maintenance on saline or 0.32 mg/kg/hr amphetamine on 
baseline ICSS performance in rats subsequently tested with cocaine (A,B), MDPV 
(C,D), or methamphetamine (E,F).  Abscissae: Brain stimulation frequency in log 
Hz.  Ordinates: % Maximum control rate.  All points show mean±SEM from N=6 rats, 
and filled points indicate significantly different from “Pre-pump Baseline” as determined 
by 2-way ANOVA followed by the Holm-Sidak post hoc test (p < 0.05). In all saline 
groups (panels A, C, and E), there was a main effect of frequency, but no main effect of 
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day and no significant interaction. In all amphetamine groups (panels B, D, and F), there 
were main effects of frequency and day, as well as a significant interaction. Interaction 
results are as follows: (B) F(9,45) = 3.45, p = 0.0027, (D) F(9,45) = 4.18, p = 0.0006, (F) 
F(9,45) = 3.24, p = 0.0041. 
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Figure 4-3. Effects of cocaine (A, B), MDPV (C, D), and methamphetamine (E, F) on 
ICSS on day 7 of treatment with either saline (A, C, E) or 0.32 mg/kg/hr amphetamine 
(B, D, F). Abscissae: Brain stimulation frequency in log Hz.  Ordinates: % Maximum 
control rate.  All points show mean±SEM from N=6 rats, and filled points indicate 
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significantly different from “Baseline” as determined by 2-way ANOVA followed by the 
Holm-Sidak post hoc test (p < 0.05). For each panel, 2-way ANOVA indicated significant 
main effects of frequency, all but panel D had a main effect of dose, and all but panel B 
had a significant interaction.  Interaction results for each panel are as follows: (A) 
F(27,135) = 3.93, p < 0.0001, (B) F(27,135) = 1.52, n.s., (C) F(27,135) = 11.03, p < 0.0001, (D) 
F(27,135) = 3.32, p < 0.0001, (E) F(27,135) = 9.13, p < 0.0001, (F) F(27,135) = 6.05, p < 
0.0001. Although there was no interaction in panel B, there was a main effect of cocaine 
dose (F(3,15) = 3.92, p = 0.030), and Dunnett’s post-hoc test (p < .05) indicated that 10 
mg/kg cocaine was different than baseline. 
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Figure 4-4. Effect of 0.1 mg/kg/hr amphetamine maintenance on (A) baseline ICSS and 
(B) cocaine-induced facilitation of ICSS.  Abscissae: Brain stimulation frequency in log 
Hz.  Ordinates: % Maximum control rate.  All points show mean±SEM in N=6 rats, and 
filled points indicate significantly different from (A) “Pre-Pump Baseline” or (B) 
“Baseline” as determined by 2-way ANOVA followed by the Holm-Sidak post hoc test (p 
< 0.05). F-values only reported for interactions. In panel A, there was a main effect of 
frequency, main effect of day, and significant interaction (F(9,45) = 3.80, p = 
.0013).  Additionally, mean (95%CL) EF50 values in log Hz differed between the pre-
pump baseline [2.03 (2.01-2.05)] and Day 7 baseline [1.92 (1.89-1.94)].  In panel B, 
there was a main effect of frequency, main effect of cocaine, and a significant dose x 
frequency interaction (F(27,135) = 5.60, p < .0001).  Additionally, cocaine produced dose-
dependent and significant decreases in mean (95%CL) EF50 values: Baseline, 1.92 
(1.89-1.94); 1.0 mg/kg cocaine, 1.84 (1.80-1.88); 3.2 mg/kg cocaine, 1.80 (1.72-1.83); 
10 mg/kg cocaine, 1.74 (1.57-1.80).  
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Figure 4-5. Effects of cocaine (A, B), MDPV (C, D), and methamphetamine (E, F) on 
NAc DA (A, C, E) and 5-HT (B, D, F) levels. Abscissae: Time in minutes relative to test-
drug injection. Vertical line at 20 min indicates earliest time of drug effect (see 
Methods). Ordinates: % of Baseline DA or 5-HT.  All points show mean±SEM for N=6 
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rats, and filled points indicate significantly (p < .05) different from the 10-min time point. 
Statistical results are as follows: (A) saline: not significant, 1.0 mg/kg: F(9,45) = 10.33, p < 
0.0001, 3.2 mg/kg: F(9,45) = 9.28, p < 0.0001, 10.0 mg/kg: F(9,45) = 16.62, p < 0.0001; (B) 
saline: F(9,45) = 3.97, p = 0.0009, 1.0 mg/kg: F(9,45) = 7.74, p < 0.0001, 3.2 mg/kg: F(9,45) = 
2.32, p = 0.0305, 10.0 mg/kg: F(9,45) = 6.91, p < 0.0001; (C) 0.1 mg/kg: F(9,45) = 13.13, p 
< 0.0001, 0.32 mg/kg: F(9,45) = 24.64, p < 0.0001, 1.0 mg/kg: F(9,45) = 10.33, p < 0.0001; 
(D) no significant effects; (E) 0.1 mg/kg: F(9,45) = 9.27, p < 0.0001, 0.32 mg/kg: F(9,45) = 
11.89, p < 0.0001, 1.0 mg/kg: F(9,45) = 10.26, p < 0.0001; (F) 0.1 mg/kg: not significant, 
0.32 mg/kg: F(9,45) = 4.44, p = 0.0003, 1.0 mg/kg: F(9,45) = 7.37, p < 0.0001. 
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Figure 4-6. Effects of cocaine (A, B), MDPV (C, D), and methamphetamine (E, F) on 
NAc DA (A, C, E) and 5-HT (B, D, F) levels after saline or amphetamine treatment. 
Abscissae: Time in minutes relative to test drug injection. Vertical line at 20 min 
indicates earliest time of drug effect (see Methods). Ordinates: change from baseline 
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DA or 5-HT in pg/9µl. Note that there is a different range used in DA panels (A, C, E) 
versus 5-HT panels (B, D, F) due to lower 5-HT levels in the NAc. All points show 
mean±SEM for N=6 rats, and filled points indicate significantly (p < .05) different from 
the 10-min time point. Statistical results are as follows: (A) saline: F(9,45) = 10.65, p < 
0.0001, amphetamine: F(9,45) = 1.26, n.s.; (B) saline: F(9,45) = 3.68, p = 0.0016, 
amphetamine: F(9,45) = 2.68, p = 0.0224; (C) saline: F(9,45) = 5.13, p < 0.0001, 
amphetamine: F(9,45) = 1.56, n.s.; (D) saline: F(9,45) = 0.90, n.s., amphetamine: F(9,45) = 
3.16, p = 0.0019; (E) saline: F(9,45) = 10.31, p < 0.0001, amphetamine: F(9,45) = 5.88, p < 
0.0001; (F) saline: F(9,45) = 13.79, p < 0.0001, amphetamine: F(9,45) = 6.63, p < 0.0001. 
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Figure 4-7. Effects of cocaine (A, B), MDPV (C, D), and methamphetamine (E, F) on 
NAc DA (A, C, E) and 5-HT (B, D, F) levels after saline or amphetamine treatment. 
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Abscissae: Time in minutes relative to test-drug injection. Vertical line at 20 min 
indicates earliest time of drug effect (see Methods). Ordinates: DA and 5-HT levels in 
the NAc in pg/9µl. Note that there is a different range used in the DA panels (A, C, E) 
versus the 5-HT panels (B, D, F) due to lower 5-HT levels in the NAc. All points show 
mean±SEM in N=6 rats, and filled points indicate significantly (p < .05) different from the 
10-min time point. Statistical results are as follows: (A) saline: F(9,45) = 10.65, p < 
0.0001, amphetamine: F(9,45) = 1.20, n.s.; (B) saline: F(9,45) = 3.68, p = 0.0016, 
amphetamine: F(9,45) = 2.46, p = 0.0224; (C) saline: F(9,45) = 5.13, p < 0.0001, 
amphetamine: F(9,45) = 1.54, n.s.; (D) saline: F(9,45) = 0.91, n.s., amphetamine: F(9,45) = 
3.61, p = 0.0019; (E) saline: F(9,45) = 10.31, p < 0.0001, amphetamine: F(9,45) = 5.87, p < 
.0001; (F) saline: F(9,45) = 13.79, p < 0.0001, amphetamine: F(9,45) = 6.63, p < 0.0001. 
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Figure 4-8.  Coronal sections showing probe placements in rats used in microdialysis 
studies. Numbers indicate anterior position of slice relative to bregma. Figures were 
produced based on comparisons to Paxinos and Watson, 2007. 
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Chapter V 
Discussion 
 
Summary 
 The overall focus of this dissertation has been on the effectiveness of 
amphetamine maintenance to treat cocaine use disorder. Amphetamine maintenance 
has been shown to decrease metrics of cocaine use in humans, nonhuman primates, 
and rodents (Banks et al, 2015a; Rush et al, 2010; Thomsen et al, 2013). However, 
amphetamine is not an ideal pharmacotherapy for cocaine use disorder because it 
possesses abuse liability of its own and it only works for about 30% of users. There is 
need for a better pharmacotherapy that is more effective and has less abuse liability. 
Toward that end, chapters II and III of this dissertation focused on development of the 
non-human primate half of a non-human primate-to-human translational model for 
testing potential pharmacotherapies for cocaine use disorder. We found that both food 
pellets and cocaine maintained responding in a dose- and magnitude-dependent 
manner and that non-human primates would respond for these reinforcers in a session 
that was set up to mirror the human laboratory procedure. Once choice between the 
reinforcers was introduced, non-human primates chose between food pellets and 
cocaine, and their choice behavior was sensitive to changes in cocaine dose as well as 
food reinforcer magnitude. This procedure was then validated using amphetamine and 
the amphetamine prodrug, lisdexamfetamine. These drugs decreased cocaine choices 
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in non-human primates, but did not produce full reallocation of behavior toward the food 
alternative. The effects seen with amphetamine and lisdexamfetamine provided some 
preliminary evidence that this procedure may be able to predict treatment effects of 
new, potential pharmacotherapies for cocaine use disorder. 
 The experiments in chapter IV of this dissertation focused on elucidating the 
mechanism of amphetamine effects on cocaine-taking behavior. Amphetamine 
maintenance was tested against the abuse-related effects of cocaine, MDPV, and 
methamphetamine in ICSS and microdialysis. In line with the clinical effects, 
amphetamine maintenance attenuated the abuse-related behavioral and neurochemical 
effects of cocaine and was less effective in both procedures against the abuse-related 
effects of methamphetamine. Amphetamine maintenance blocked the abuse-related 
neurochemical but not behavioral effects of MDPV, suggesting that amphetamine 
maintenance would be less effective against MDPV use disorders than cocaine use 
disorders. These experiments provided insight into the mechanism of amphetamine 
maintenance decreasing cocaine use. 
 
Development of a Novel Translational Non-Human Primate Choice Procedure 
 These experiments were conducted to develop a model of non-human primate 
cocaine-versus-food choice that may help streamline the medication development 
process for cocaine use disorder. The medication development process benefits from a 
strong preclinical component that can screen out compounds that would be unlikely to 
be effective in the clinic or that may produce unwanted side effects. Screening out those 
compounds would reduce risks and costs associated with running unsuccessful human 
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laboratory drug self-administration or clinical trials. However, procedural differences 
between preclinical and human laboratory experimental designs could affect this 
translational process.  For example, some preclinical drug self-administration studies 
train subjects to self-administer cocaine (or some other abused drug) under simple 
schedules of reinforcement, under which cocaine is the only reinforcer available, and 
the primary dependent variable is rate of responding or rate of reinforcement (Mello and 
Negus, 1996; Negus and Banks, 2011). Test drugs can then be evaluated for their 
effectiveness to reduce rates of cocaine self-administration, and drugs that reduce 
cocaine self-administration are sometimes suggested as candidate pharmacotherapies 
that might reduce clinical cocaine use. However, these simplistic preclinical 
experimental designs differ from clinical patterns of abuse and treatment in numerous 
respects. Three will be mentioned here. First, clinical drug abuse exists in a complex 
environment in which other reinforcers are available, and subjects allocate their 
behavior between these reinforcers. Under these circumstances, cocaine abuse is 
manifested as excessive use of cocaine at the expense of behaviors maintained by 
other, more adaptive reinforcers, and a goal of treatment is not only to reduce cocaine 
use, but also to promote reallocation of behavior away from cocaine use and toward 
responding maintained by other reinforcers. Second, treatments for drug abuse in 
general and cocaine abuse in particular are not administered acutely, but rather are 
administered chronically for weeks, months, or years, and it is well established that 
treatment effects on drug self-administration can change from acute to chronic 
treatment. Lastly, treatments can decrease rates of cocaine self-administration not only 
by reducing sensitivity to the reinforcing effects of cocaine, but also by impairing the 
 98 
 
subject’s motoric ability to respond, and such non-selective behavioral depression is 
undesirable in a candidate medication. These types of differences in preclinical 
research and clinical practice likely contribute to failed translation of results. As one 
example, acute administration of dopamine receptor antagonists like flupenthixol dose-
dependently decreases cocaine self-administration under simple schedules of 
reinforcement, and this type of result contributed to consideration of these antagonists 
as treatments for cocaine abuse (Ettenberg et al, 1982; Negus et al, 1996).  However, 
dopamine receptor antagonists have failed in the clinic, and further preclinical research 
has suggested that this failure reflects (a) the non-selective effects of DA receptor 
antagonists to produce general behavioral disruption, (b) the potential for tolerance to 
develop to the motoric effects of DA receptor antagonists during chronic treatment, and 
(c) the potential for DA receptor antagonists to increase choice of cocaine over 
alternative reinforcers when cocaine self-administration is studied using choice 
procedures (Grabowski et al, 2004b). 
Keeping those factors in mind, the homologous procedure developed here for 
testing pharmacotherapies in non-human primates and humans needed to have 2 
important properties: 1) to be able to differentiate between decreases in cocaine-taking 
due to a decrease in the reinforcing properties of cocaine as opposed to a decrease due 
to non-selective disruption of behavior, and 2) to be able to evaluate the effect of sub-
chronic treatment with a candidate pharmacotherapy. Choice procedures provide the 
ability to distinguish between decreases in cocaine-taking due to general behavioral 
disruption and effects on the reinforcing properties of the drug. They also have the 
advantage of being able to detect pharmacotherapies that may promote reallocation of 
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behavior away from cocaine self-administration and toward alternative non-drug 
reinforcers. Choice procedures have also been used to test sub-chronic treatment 
regimens of pharmacotherapy dosing in preclinical (e.g. Banks et al, 2015a) and human 
(Rush et al, 2010) drug self-administration choice procedures. To mitigate the risk of 
procedural variables confounding results, the non-human primate cocaine self-
administration choice procedure developed in this dissertation was back-translated from 
a human laboratory choice procedure. This allowed for homology between the 
preclinical and human laboratory self-administration choice procedures and allowed 
equivalent IV doses of self-administered cocaine to be tested between the procedures. 
There are several unique features to the choice sessions in these studies as compared 
to other preclinical choice procedures. The sessions are long (5 hrs), substantial 
responding is required for each reinforcer (200-1200 responses depending on how far 
the monkey makes it in the progressive-ratio progression), there are few choices per 
session (9), the self-administration cocaine doses for the non-human primates are 
based on the human doses, maintenance drug doses are based on the doses that can 
be tested in humans (although the monkey study may test a broader range of doses of 
the maintenance medications), there is a sample trial, and the discriminative stimuli that 
indicate availability of the reinforcers do not change based on the dose of cocaine or 
magnitude of food pellets available. These variables are all similar to the human 
laboratory procedure, and many are different from current preclinical choice procedures. 
 Despite these many similarities, there are also several differences between the 
preclinical procedure and the human laboratory procedure. The non-drug alternative 
reinforcer in the non-human primate studies is food pellets, but in the humans, it is 
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money. Food does not work well as the alternative reinforcer in humans (Stoops et al, 
2010), and although it might be possible to set up a token economy as an alternative 
reinforcer in non-human primate research, the training required would be time- and 
cost-prohibitive for use in this choice procedure. Another difference lies in the 
maintenance medication administration. In the human laboratory, patients typically 
receive oral doses of the maintenance medication at least 2 times a day, while in the 
non-human primate sessions the doses are given IV, and in the case of amphetamine 
via continuous infusion. Oral dosing of maintenance medication in non-human primates 
is possible, but it is difficult to ensure that the monkey receives the full dose of the 
maintenance. One strategy to evaluate equivalence of dosing in preclinical and clinical 
studies is to compare plasma levels of drugs and metabolites.  Plasma amphetamine 
levels obtained during amphetamine maintenance in monkeys were reported in Chapter 
III, and these levels will be compared to those obtained in parallel human studies 
conducted by our collaborator Dr. Josh Lile at the University of Kentucky.  
During initial training, monkeys first responded for food pellets alone and cocaine 
alone as single reinforcers under the progressive-ratio discrete trials procedure. Both 
reinforcers maintained behavior greater than vehicle or no pellets, and the largest dose 
or magnitude maintained completion of all the choices. The monkeys then started 
choice sessions and chose between cocaine and food in a dose and magnitude-
dependent manner. As the dose of cocaine increased, cocaine choices also increased, 
and as the magnitude of pellets increased, more choices were completed for pellets. 
This was consistent with the human data collected at the University of Kentucky. High 
cocaine doses maintained high proportions of cocaine choice, and larger money 
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amounts increased money choice. The parametric work up of these two procedures 
showed that the non-human primate and human choices were correlated (Lile et al, 
2016). 
In the non-human primates, lisdexamfetamine and amphetamine maintenance 
decreased cocaine choices without decreasing food choices. These data are consistent 
with the published data on amphetamine maintenance decreasing cocaine use 
(Grabowski et al, 2004a; Levin et al, 2015). Even so, there is an apparent discrepancy 
with lisdexamfetamine in that a clinical trial using lisdexamfetamine for cocaine use 
disorder did not show positive results (Mooney et al, 2015). However, the clinical trial 
was limited by dose and could only test up to doses that were approximately equivalent 
to the 1.0 mg/kg/day lisdexamfetamine dose in the non-human primate study, which 
was not effective to decrease cocaine choice in non-human primates either. These 
results support using this novel self-administration choice procedure in non-human 
primates to predict with greater accuracy human laboratory and clinical results for 
potential pharmacotherapies to treat cocaine use disorder.    
 
Mechanisms of Amphetamine Maintenance-Induced Decreases in Abuse-Related 
Effects of Cocaine 
 These studies were conducted to gain an understanding of the neurobiological 
mechanisms underlying the effect of amphetamine on the abuse-related effects of 
cocaine. In these studies, cocaine, MDPV, and methamphetamine produced facilitation 
in ICSS and an increase in NAc DA levels, and the potencies of these drugs to facilitate 
ICSS were similar to their potencies to increase NAc DA; however, only cocaine and 
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methamphetamine produced increases in NAc 5-HT levels. Amphetamine maintenance 
also produced an increase in baseline ICSS as well as an increase in baseline NAc DA 
levels, but not 5-HT levels. These findings support the hypothesis that facilitation in 
ICSS may reflect increases in DA versus 5-HT levels (Bauer et al, 2014; Suyama et al, 
2016).  
 Amphetamine maintenance attenuated the facilitation of ICSS by cocaine and 
blocked the DA-increasing effect, but not the 5-HT-increasing effect, of cocaine. Both 
results are consistent with the clinical effectiveness of amphetamine to decrease 
metrics of cocaine use. Amphetamine maintenance did not block the ICSS facilitation or 
the NAc DA and 5-HT increases caused by methamphetamine. This profile of effects is 
consistent with the clinical ineffectiveness of amphetamine maintenance on 
methamphetamine-taking behavior. Amphetamine maintenance did not block the ICSS 
facilitation by MPDV, did block the NAc DA increase, and did not alter the lack of 5-HT 
increase by MDPV. These data suggest that amphetamine maintenance would be less 
effective to treat MDPV use disorder than cocaine use disorder.  
 Taken together, these data suggest that amphetamine decreases cocaine use by 
producing a selective increase in baseline DA levels and attenuating the DA, but not 5-
HT, increase produced by cocaine. The MDPV data in particular suggest that preserving 
the 5-HT increasing effect of cocaine may be important in attenuating the abuse-related 
behavioral effects of cocaine during amphetamine maintenance. Serotonin can regulate 
DA release, although this relationship is complex because a serotonergic drug can 
increase or decrease DA depending on the drug used and the 5-HT receptor subtypes 
targeted (Fischer and Ullsperger, 2017; Howell and Cunningham, 2015).  
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The disconnect between the lack of DA increase after an injection of MDPV 
during amphetamine maintenance and the retention of the abuse-related behavioral 
effects in ICSS is difficult to explain. If DA is not increasing after MDPV administration, 
what else could be causing ICSS facilitation? Figure 5-1 presents a diagram showing 
the circuit that could allow this effect to happen. A major difference between ICSS and 
microdialysis procedures is that in ICSS, brain areas are being electrically stimulated. 
When the electrode is placed in the medial forebrain bundle at the level of the lateral 
hypothalamus, the electrode is thought to stimulate descending glutamatergic fibers that 
synapse onto VTA DA neurons. Under normal circumstances, the activity of these VTA 
neurons is increased after electrical stimulation. It is my hypothesis that the 5-HT inputs 
to the VTA and RMTg dampen the firing rate of the VTA neurons after an injection of 
cocaine during amphetamine maintenance, and the DAT-blocking action of cocaine 
offsets the decrease in firing rate of the DA neurons, so there is no net effect on DA 
levels. Without the 5-HT increase, administration of MDPV would not decrease firing 
rate of VTA neurons, so stimulation of the glutamatergic inputs to the VTA would 
produce an increase in firing of DA neurons and release of DA and the DAT-inhibiting 
properties of MDPV would result in an increase in DA in the NAc, which is expressed as 
facilitation in ICSS. This differential effect would not show up between cocaine and 
MDPV in microdialysis during amphetamine maintenance because there is no brain 
stimulation to increase VTA DA neuron firing. This hypothesis could be tested by 
placing a stimulating electrode into either the medial forebrain bundle or the VTA and a 
guide cannula in the NAc during amphetamine maintenance. Stimulation of the medial 
forebrain bundle or the VTA should produce DA increases in the NAc above the high 
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DA baseline produced by amphetamine maintenance and MDPV should enhance the 
effect while cocaine should not. 
These data also suggest that maintenance drugs that are more selective for 
SERT than DAT would be less effective to treat cocaine abuse. Drugs such as selective 
serotonin reuptake inhibitors have been tested in clinical trials as well as in preclinical 
procedures and have not been effective to decrease cocaine use, supporting this 
hypothesis (Pani et al, 2011).  
 The mechanism of amphetamine maintenance effects on cocaine use appears to 
be in blunting the DA increase of cocaine while maintaining the 5-HT increase of 
cocaine, but it is still not clear how the cocaine or MDPV DA increase is blunted by 
amphetamine, but the methamphetamine DA increase is not. Amphetamine 
maintenance also increased baseline levels of DA. Dopamine levels can be influenced 
by effects on at least 3 factors: 1) firing rate of the DA neurons, 2) DA uptake rate, and 
3) DA release rate (Siciliano et al, 2015). Uptake inhibitors such as cocaine are 
sometimes referred to as “activity-dependent” drugs, meaning that their effects depend 
on the activity of the DA neurons, so the 3 factors that affect basal DA levels may also 
be expected to influence the effects of uptake inhibitors. If a consequence of 
amphetamine maintenance is decreased DA uptake rate, it could explain both the 
increased DA baseline and the blunted DA-increasing effect of uptake inhibitors (see 
figure 5-2). The amphetamine maintenance regimen sufficient to blunt the behavioral 
and neurochemical effects of cocaine was not sufficient to decrease DAT binding sites 
or change affinity for a DAT ligand in the striatum, so the effect of amphetamine is not 
mediated by a decrease in DAT. However, it is still a possibility that amphetamine 
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maintenance has decreased DAT function. Studies have found that acute exposure to 
releasers such as amphetamine can cause a change in DAT function and conformation 
such that DATs are more likely to be open toward the intracellular environment than the 
extracellular environment (Kahlig and Galli, 2003). This decrease in normal DAT 
function overlaps with the effect caused by cocaine, so adding cocaine will not have any 
further effect on DA levels and may decrease functional binding sites for cocaine even if 
DAT expression has not been changed. 
It is possible that, during maintenance conditions, amphetamine has reached an 
equilibrium with DA release, DAT function, and negative feedback mechanisms such as 
autoreceptor activation or activation of neurons that provide inhibitory input to the VTA 
neurons, and addition of an uptake inhibitor to the system upsets the balance. An 
uptake inhibitor would compete with amphetamine for access to the binding site of DAT 
and would prevent DAT-mediated efflux of DA out of the cell (Kahlig et al, 2005). The 
decrease in DAT-mediated efflux could be enough to offset any increase in DA that 
would normally be seen when an uptake inhibitor binds to DAT. Another possibility is 
that amphetamine brings a depolarizing current with it as it is transported into the 
neurons, possibly resulting in increased neuronal firing rates (Cameron et al, 2015); 
however, when cocaine binds to the transporter, it induces a hyperpolarizing current 
that may reduce neuronal firing rates. These competing currents could offset each other 
and result in no change in DA levels. The current studies do not provide any indication 
of which possibility might be more likely. Studies that evaluate the effects of 
amphetamine maintenance on stimulated DA release, autoreceptor function, and 
membrane potential are needed to elucidate these potential mechanisms. 
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Future Directions 
 The data contained within this dissertation support the hypothesis that 
medication development should focus on blunting the DA-increasing effects of cocaine 
while maintaining the 5-HT-increasing effects of cocaine. The pharmacotherapy studied 
in this dissertation, amphetamine, produced a sustained increase in baseline DA levels 
and blocked the DA-increasing effect of 2 uptake inhibitors (cocaine and MDPV) while 
failing to block the DA increase by a releaser. Drugs that produce sustained decreases 
in DA levels and blunt the DA-increasing effects of cocaine have not yet been tried in 
this procedure. Several drugs, when given as an acute injection, can blunt the DA 
increase by cocaine, but few have been tried using maintenance dosing in 
microdialysis. Such drugs include lorcaserin (Gerak et al, 2016), a 5-HT2C receptor 
agonist. The localization 5-HT2C receptors has been characterized and they are found in 
areas of the brain that have the potential to influence DA, so this makes them intriguing 
targets for candidate pharmacotherapies (Howell and Cunningham, 2015). The current 
evidence in the literature is that lorcaserin, or the combination of lorcaserin with a 5-
HT2A antagonist, decrease cocaine taking by decreasing the rate of DA-neuron firing 
and attenuate the DA increase by cocaine (Cunningham et al, 2013; Gerak et al, 2016). 
There is also evidence that an antagonist at the 5-HT2C receptor (SB242084) can 
produce increases in NAc DA levels (Devroye et al, 2013), but does not facilitate ICSS 
up to a dose of 1 mg/kg (Bauer et al, 2015; Katsidoni et al, 2011). This presents a set of 
drugs that, when administered acutely, can increase or decrease NAc DA levels. These 
drugs have not been tested in maintenance conditions in microdialysis, so it remains to 
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be seen what the effects of long-term treatment are on basal NAc DA levels and 
cocaine-induced NAc DA increase. The findings in this dissertation with amphetamine 
maintenance suggest that a sustained increase in NAc DA levels is associated with a 
blunted DA response to cocaine. If the acute DA-increasing effects of the 5-HT2C 
antagonist drugs maintain over several days of administration, they could present a way 
to learn if a sustained increase in NAc DA is sufficient to attenuate the abuse-related 
effects of cocaine.  
 These drugs could first be tested acutely in rats using microdialysis and ICSS to 
identify dose ranges. The effects of maintenance with 5-HT2C agonists and antagonists 
could then be tested against the abuse-related effects of cocaine in ICSS and 
microdialysis. If a drug is identified in these procedures as attenuating either the abuse-
related behavioral or neurochemical effect of cocaine, it would be a good candidate 
pharmacotherapy to test in the non-human primate choice procedure described earlier 
in this dissertation. If the drug reduces cocaine choices without producing unwanted 
side effects in the non-human primate studies, it would then be an excellent choice to 
move into the human laboratory choice testing.  
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Figure 5-1. Diagram showing the brain circuit affecting ICSS. Stimulation of the 
descending glutamate neurons increases activity in the VTA DA neurons, increasing DA 
release in the NAc. There are inhibitory 5-HT receptors located on VTA DA cell bodies 
and on the DA terminals in the NAc and excitatory 5-HT receptors on cell bodies in the 
RMTg that will produce an increase in inhibitory input to the VTA. An increase in 5-HT 
levels in the VTA, NAc and RMTg could decrease firing rate of the VTA neurons so as 
to offset any increase caused by excitatory input from the ICSS stimulation. 
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Figure 5-2. A depiction of DA neurons in the NAc at baseline (A), with the addition of 
cocaine (B), during amphetamine maintenance (C), and during amphetamine 
maintenance with cocaine (D). During baseline conditions (A), the DA neurons are firing 
at a basal level, but the functioning DATs keep basal DA levels low. When cocaine is 
added to this system (B), the DATs are inhibited and DA levels rise, activating post-
synaptic DA receptors as well as autoreceptors on the presynaptic DA neuron. During 
amphetamine maintenance (C), DATs mediate efflux of DA out of the cell rather than 
bringing DA into the cell. This results in high levels of baseline DA levels and increased 
activation of postsynaptic DA receptors as well as autoreceptors. Adding cocaine on top 
of the amphetamine maintenance (D) may produce little change in extracellular DA 
because DATs are already not functioning at full capacity and DA levels are already 
high. However, cocaine can still act at SERT to increase 5-HT levels, so it may still be 
able to decrease DA neuron firing (see figure 5-1 for circuit). 
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